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ABSTRACT
The microtubule associated protein, tau, is involved in regulating microtubule
stability and axonal transport. When tau becomes hyperphosphorylated it can
disassociate from the microtubules and start to aggregate. These tau aggregates are
the hallmarks of many diseases known as tauopathies. The heat shock protein 90 kDa
(Hsp90) chaperone network is highly involved in modulating client proteins, including
tau. However, during aging and disease the Hsp90 chaperone network becomes highly
imbalanced with some Hsp90/co-chaperone complexes increasing, while others are
repressed. This imbalance in Hsp90/co-chaperone complexes could result in a
worsening of tau pathology in Alzheimer’s disease.
Hsp90 inhibition has been of interest as a potential therapeutic for tauopathies for
many years. However, issues with toxicity and bioavailability have dampened
enthusiasm for Hsp90 as a viable therapeutic target. Hsp90 co-chaperones are
currently being investigated for as potential therapeutic targets for tauopathies, with the
hope that targeting co-chaperones will lead to more specific targeting without toxicity.
One co-chaperone that has the potential to become a therapeutic target for tauopathies
is the activator of Hsp90 ATPase homolog 1 (Aha1).
Aha1 is the only known stimulator of the ATPase of Hsp90, so targeting this
particular co-chaperone could potentially mimic the effects of Hsp90 inhibition with more
vii

specificity. In this study we found that Aha1 enhanced Hsp90-mediated tau aggregation
and increased insoluble tau accumulation in vitro. Additionally, a novel Aha1 inhibitor
was able to reduce the formation of insoluble tau in vitro. We also investigated the
effects of Aha1 overexpression in the rTg4510 mouse model, which is a tauopathy
model that stably overexpresses the P301L mutation of tau. Overexpression of Aha1 in
these mice increased the accumulation of insoluble and oligomeric tau. Furthermore,
Aha1 overexpression led to cognitive deficits and neurotoxicity. Due to the effect of
Aha1 overexpression on tau we wanted to investigate the effects of Aha1 knock-down in
the rTg4510 mice. Incredibly, Aha1 knock-down led to reductions in pathological
Gallyas silver positive tau tangles and was able to rescue neuronal loss. Overall, this
work highlights Aha1 as an important regulator of tau pathology through Hsp90. The
Hsp90/Aha1 complex could provide a novel therapeutic target for the treatment of
tauopathies.
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Chapter One1:
Imbalances in the Hsp90 chaperone machinery: Implications for tauopathies
1.1 Abstract
The ATP-dependent 90kDa heat shock protein, Hsp90, is a major regulator of
protein triage, from assisting in nascent protein folding to refolding or degrading aberrant
proteins. Tau, a microtubule associated protein, aberrantly accumulates in Alzheimer’s
disease (AD) and other neurodegenerative diseases, deemed tauopathies. Hsp90 binds
to and regulates tau fate in coordination with a diverse group of co-chaperones.
Imbalances in chaperone levels and activity, as found in the aging brain, can contribute
to disease onset and progression. For example, the levels of the Hsp90 co-chaperone,
FK506-binding protein 51 kDa (FKBP51), progressively increase with age. In vitro and in
vivo tau models demonstrated that FKBP51 synergizes with Hsp90 to increase neurotoxic
tau oligomer production. Inversely, protein phosphatase 5 (PP5), which dephosphorylates
tau to restore microtubule-binding function, is repressed with aging and activity is further
repressed in AD. Similarly, levels of cyclophilin 40 (CyP40) are reduced in the aged brain
and further repressed in AD. Interestingly, CyP40 was shown to breakup tau aggregates
in vitro and prevent tau-induced neurotoxicity in vivo. Moreover, the only known stimulator
of Hsp90 ATPase activity, Aha1, increases tau aggregation and toxicity. While the levels
of Aha1 are not significantly altered with aging, increased levels have been found in AD
brains. Overall, these changes in the Hsp90 heterocomplex could drive tau deposition
and neurotoxicity. While the relationship of tau and Hsp90 in coordination with these co1

chaperones is still under investigation, it is clear that imbalances in these proteins with
aging can contribute to disease onset and progression. This chapter highlights the current
understanding of how the Hsp90 family of molecular chaperones regulates tau or other
misfolded proteins in neurodegenerative diseases with a particular emphasis on the
impact of aging.
____________________
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Portions of this work were previously published (Shelton LB et al., 2018) and are used with
permission of the publisher.

1.2 Introduction
Aging is the biggest risk factor for developing a neurodegenerative disease, but
the specific factors which cause these predominantly sporadic diseases are still under
investigation (1). As cells within the body age, the cellular homeostasis network must deal
with an increasing amount of misfolded and aggregated proteins that can pathogenically
accumulate leading to cell death. Aging is caused by compromised cellular homeostasis,
fitness, and plasticity, leading to degeneration and cell death in vital organs. According to
the ‘garbage catastrophe’ hypothesis, aged differentiated cells lose the capacity to
dispose of damaged and malfunctioning proteins (2). Such damaged proteins can
assume cytotoxic properties, and their constant removal is thus essential for cell survival.
Not only does aging lead to an increased likelihood of protein misfolding and aggregation,
it is compounded by a decrease in the efficiency of the protein degradation machinery.
The activity of both the proteasome, which is the main mechanism of protein degradation
(3, 4), and chaperone-mediated autophagy (CMA; (5)) is significantly impaired with aging
and is especially pronounced in post-mitotic cells, such as neurons, potentially resulting
2

in neurodegenerative disease (2). Fortunately, there is a system in place to help the body
maintain proteostasis in times of stress and disease: the molecular chaperone network
(6). This network is comprised of a diverse family of proteins which contains members
that are constitutively expressed to help in normal cell maintenance as well as members
that become activated during times of stress. All of these chaperones assist in various
ways to help fold, refold and degrade misfolded proteins.
The molecular chaperone network is comprised of diverse families of heat shock
proteins (Hsps) that are divided based on their molecular mass. The small Hsps regulate
general protein aggregation, Hsp40s regulate Hsp70 ATP hydrolysis, Hsp70 folds
proteins during translation, and Hsp90 maintains and triages a subset of clients (7, 8).
While Hsp70 and Hsp90 perform many overlapping roles in the cell, Hsp90 shows more
client selectivity. Hsp90 requires ATP to perform these functions including protein
degradation, protein folding, prevention of protein aggregation, and protein modification
(9). These regulatory processes are particularly important for intrinsically disordered
proteins (IDPs), which have a high propensity to aggregate (10).
Hsp90 binds to one of these IDPs, tau, in a broad region that includes aggregation
prone areas (11). Tau normally functions to stabilize the microtubules and regulate axonal
transport (12). The pathological accumulation of tau is a hallmark in several
neurodegenerative disorders collectively termed tauopathies (13); a series of diseases
including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), Pick’s
disease, and chronic traumatic encephalopathy (CTE; (12)). Currently there are no
treatment options available that regulate tau pathogenesis (14), therefore more work
needs to be done to identify potential tau regulating therapeutic strategies.
3

A promising avenue to target tau is through Hsp90 inhibition. In fact, Hsp90
ATPase-inhibitors rapidly degrade tau aggregates in vivo (15, 16), but these inhibitors
have not yet been successful in clinical trials due to lack of efficacy and associated
toxicities (17–19). However, Hsp90 regulates tau and other aggregating proteins in
coordination with a diverse group of co-chaperones (10). In fact, the levels of many of
these co-chaperones have been shown to change with aging, which can alter the fate of
tau and potentially contribute to disease onset or severity (20, 21). It is possible that a
more successful treatment strategy may be found by a therapeutic aimed toward
regulating these co-chaperones or Hsp90/co-chaperone heterocomplexes (22, 23). This
chapter discusses the involvement of Hsp90 and its co-chaperones in disease and how
alterations in levels and activity with aging can affect this process (Table 1.1). Current
Hsp90 therapeutic interventions for neurodegenerative diseases will also be reviewed.
1.3 Hsp90
Hsp90 is critical to maintaining proteostasis (21) and accounts for up to 6% of all
protein within the cell during times of stress (24, 25). Hsp90 consists of three domains:
an N-terminal ATP-binding domain, a middle domain, and a C-terminal domain
responsible for the inherent dimerization of the protein (26). Hsp90 requires ATP in order
to dimerize and properly assist in protein folding. The Hsp90 ATPase cycle consists of
four stages: the ATP-bound state, an initial intermediate state (I1), a second intermediate
state (I2), and finally a closed state in which ATP hydrolysis occurs (26). There are several
different isoforms of Hsp90: cytosolic Hsp90, which includes Hsp90α (stress-inducible)
and Hsp90β (constitutively active); an endoplasmic reticulum (ER) isoform, glucloseregulated protein 94 (GRP94); and a mitochondrial associated isoform, tumor necrosis
4

factor receptor associated protein 1 (TRAP1) (24, 27). Very little is known about the
organelle specific Hsp90 isoforms, so this chapter will focus on cytosolic Hsp90.
The two different cytosolic forms of Hsp90 are 86% genetically identical and have
93% amino acid sequence homology, showing lots of similarities in structure and function.
However, there are some differences that set these two isoforms apart. The first
difference is the viability of Hsp90 knock-out mice. Mice lacking Hsp90β are embryonically
lethal and do not survive past day 9, whereas mice lacking Hsp90α are viable but leads
to sterility in male mouse (28, 29). There are also some differences in the cellular
functions of Hsp90α and Hsp90β. Hsp90α is involved in growth promotion, cell cycle
regulation, stress-induced cytoprotection, and cancer cell invasiveness; whereas Hsp90β
is involved with early embryonic development, germ cell maturation, cytoskeletal
stabilization, cellular transformation, signal transduction, and long-term cell adaptation
(30, 31). While there are some general functional differences between the two cytosolic
isoforms more studies are needed to better understand the role of these different isoforms
on tau pathology.
Alterations in chaperone expression are commonly seen in aging, leading to
complications within the Hsp90 chaperone network. In fact, recent work has shown the
levels of many Hsp90 co-chaperones are also altered in the aged brain (21). These cochaperones are necessary for client selection and triage. There are two main categories
of Hsp90 co-chaperones: tetratricopeptide repeat (TPR) and non-TPR containing (32).
Therefore, changes in Hsp90 levels are part of a larger imbalance in the chaperone
network, which contribute to aging and age-related neurodegenerative disorders.

5

1.4 Aha1
The activator of Hsp90 ATPase homolog 1 (Aha1) works as a co-chaperone to
stimulate the ATPase function of Hsp90 to regulate the folding and activation of client
proteins. Pearl and Prodromou were the first to identify the role of Aha1 as a stimulatory
co-chaperone of Hsp90 (33). Aha1 is a relatively small protein of 38kDa that is highly
conserved from yeast to man (33, 34). There is also an Aha1-related protein, Aha2, which
can only be found in higher eukaryotes although this protein has not been well
characterized (35). Aha1 is highly expressed throughout tissues such as the kidney, brain,
heart, and skeletal muscles and is mainly localized to the cyctoplasm within cells (35).
Aha1 knock-out mice are available and viable but there is currently no information on any
phenotypic deficits (The Jackson Laboratory; Stock No: 029805).
Aha1 interacts with Hsp90 independent of its nucleotide status and allows the
Hsp90 ATPase cycle to skip the I1 phase, thus accelerating the progression of the
ATPase cycle dramatically (26, 36). Interestingly, only one Aha1 protein is required to
fully stimulate the ATPase activity of Hsp90 even though there are two binding pockets
on each Hsp90 dimer (36). One study suggests that SUMOlyation of a conserved lysine
on Hsp90 (K191) facilitates the recruitment of Aha1 (37). Another study found that c-Abl
phosphorylation of the tyrosine residue Y223 in human Aha1 promotes its interaction with
Hsp90 (38). Perhaps both of these post-translational modifications need to occur for
Hsp90 and Aha1 to interact, however, it is possible that either of these PTMs are
sufficient. While the c-Abl tyrosine kinase is important in promoting the interaction
between Aha1 and Hsp90, it also plays a significant role in tau phosphorylation. One
study has shown that amyloid-β-peptide (Aβ) activates c-Abl, which then goes on to
6

phosphorylate tau through Cdk5 activation (39). This same study found that inhibition of
c-Abl

expression

via

shRNA

decreased

both

AT8

and

PHF1

tau

in

the

APPswe/PSEN1ΔE9 transgenic mouse (39). These findings suggest that c-Abl could be
a link between tau and Aha1, because when c-Abl levels are increased, there is an
increased association between Aha1 and Hsp90 as well as an increase in tau
phosphorylation and aggregation, but more studies are needed to elucidate the specifics
of these interactions.
Aha1 has been investigated for its role in several diseases such as cancer, cystic
fibrosis, and more recently, tauopathies. In cancer cells, when c-Abl is inhibited, Aha1 is
unable to interact with Hsp90, which allows the cancer cells to become hypersensitized
to other treatments, such as Hsp90 inhibition (38). Cystic fibrosis was the first disease
that Aha1 was implicated in and, studies have shown that downregulation of Aha1 is able
to rescue the translocation of the mutant form of cystic fibrosis transmembrane
conductance regulator (CFTR) ΔF508 (40). This provides additional support for targeting
Aha1, as suppression of Aha1 is beneficial in multiple diseases. It is interesting to note
that Aha1 levels have been shown to increase with AD. In fact, we have found that Aha1
levels in the medial temporal gyrus of human brain correlated with increased tau Braak
staging (41). In the same study, we found that high levels of Aha1 in a tau transgenic
mouse model increased tau oligomers as well as neuronal loss concomitant with cognitive
deficits (41). Since Aha1 levels are repressed in aging, but are abnormally preserved in
AD, tau aggregation could be accelerated in part by Aha1 in the AD brain.

Thus,

treatments which reduce Aha1 may be beneficial for diseases such as AD and cystic
fibrosis.
7

While the Aha1/Hsp90 complex and the impact on tau is the focus of this thesis,
there are many other important co-chaperones that play a role in the complicated
dynamics of the Hsp90 chaperone network. The rest of the Hsp90 co-chaperones and
their relationship to tau will be discussed below.
1.5 TPR co-chaperones
TPR-containing Hsp90 co-chaperones interact with the C-terminal MEEVD peptide
motif on Hsp90 (27). Since Hsp90 functions as a dimer, two TPR-containing cochaperones could interact simultaneously. However, these interactions are dependent on
the isoform of Hsp90 and the repertoire of expressed co-chaperones. In fact, cochaperones do compete for binding to Hsp90 (42, 43). This competition can have
beneficial or detrimental effects on tau pathology. Known examples include cochaperones which interact with Hsp90 to promote the degradation of aberrant tau or
others which drive tau oligomerization and aggregation. Therefore, an imbalance in
protein levels with aging and AD compound this already complex competition for binding
Hsp90 to regulate tau fate (Fig. 1.1). Here, we will describe these TPR-co-chaperones,
and how their interaction with Hsp90 regulates tau.
1.5.1 Immunophilins and Immunophilin homologs
Hsp90 interacts with six immunophilins that display peptidyl-prolyl isomerase
(PPIase) activity through TPR domains including cyclophilin 40 (CyP40) and five FK506binding proteins: FKBP51, FKBP52, FKBP36, FKBP38, FKBPL/WISp39 (44–47). These
PPIases regulate the twisting of proline bonds through stabilization of the cis-trans
transition state and accelerate the isomerization process. This is particularly important for
8

tau, which has 40 proline residues that regulate phosphorylation and aggregation
propensity (48). Hsp90 also interacts with two immunophilin homologs: protein
phosphatase 5 (PP5) and XAP2/FKBP37. Altered levels of many of these immunophilins
and immunophilin-like proteins have been found in aging and AD (Table 1.1), which could
skew the competition dynamics for Hsp90 binding (discussed later in this chapter) and
may promote toxic tau accumulation.
1.5.1.1 CyP40
An interesting PPIase, CyP40, decreases in aging and is further repressed in AD
(21). CyP40 was recently shown to disaggregate tau fibrils in vitro and prevents toxic tau
accumulation in vivo preserving memory, demonstrating a neuroprotective role for CyP40
in the brain (49). The PPIase activity of CyP40 is slightly repressed when bound to Hsp90,
but under cellular stress CyP40 can release from Hsp90 increasing its isomerase and
chaperone activity (50). However, as CyP40 levels decrease with aging, it is possible that
the pool of free CyP40 is not sufficient to help disentangle aggregating proteins, like tau.
1.5.1.2 FKBP51
Contrary to the neuroprotective effects of CyP40, two FK506-binding proteins
(FKBPs) have been shown to stimulate toxic tau aggregation (20, 51, 52). One of these,
FKBP51, coordinates with Hsp90 to preserve toxic tau oligomers in vivo (Blair et al.,
2013). In fact, mice lacking FKBP51 have decreased tau levels in the brain (20, 53).
However, throughout aging, FKBP51 levels progressively increase and are further
increased in AD brain samples (Table 1.1) (20, 54). Previous studies have also shown
that FKBP51 can form complexes with tau in both human AD brain samples and control
9

samples (53). Additionally, this study showed that FKBP51 was able to stabilize
microtubules, suggesting a novel and unique function for FKBP51 (53). Taken together,
the increase in FKBP51 in aging and AD suggest that targeting FKBP51 could offer a
potential therapeutic strategy for tauopathies such as AD.
1.5.1.3 FKBP52
FKBP52 interacts both physically and functionally with tau and promotes tau
aggregation in vitro (51, 55). FKBP52 induces oligomers from both P301L and truncated
wild-type tau. Interestingly, this oligomerization is not due to the PPIase activity of
FKBP52, instead the oligomerization of tau appears to occur via molecular interaction
(52). FKBP52 can also induce aggregation of a truncated form of tau that appears to have
prion like behavior, suggesting a possible mechanism for the spread of tau pathology
throughout the brain in diseases such as AD (51). However, it is interesting to note that
FKBP52 levels are lower in the cortex of AD patients’ brains (Table 1.1) (21, 55).
1.5.1.4 FKBP36, FKBP38, and FKBPL
There are several other FKBPs that act as co-chaperones to Hsp90 including
FKBP36, FKBP38, and FKBPL (WISp39), however their relationship to tau, if any, is still
unknown at this point and so they will not be discussed in detail.
1.5.1.5 XAP2
XAP2, otherwise known as FKBP37 or Aryl hydrocarbon receptor interacting
protein (AIP), contains a PPIase homologous domain. While a direct role of XAP2 in tau
pathogenesis has not been described, studies have shown that XAP2 is activated by
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histone deacetylase (HDAC) 6, which has been linked to pathogenic tau (56–58). In
addition, XAP2 coordinates with Hsp90 to regulate glucocorticoid receptor signaling (59),
which has also been implicated in the production of pathogenic tau (60). Additional
studies are needed to determine the direct or indirect effects of XAP2 on tau pathology.
1.5.1.6 PP5
Another member of this family, protein phosphatase 5 (PP5), is repressed in aging.
PP5 is contains a PPIase homology domain, but does not display classical PPIase
activity, since it can bind FK506 (61). Instead, PP5 acts as a Ser/Thr phosphatase, which
activates when bound to Hsp90 (62). PP5 activity has been shown to be repressed in AD
(Table 1.1) (63). Studies have shown that PP5 is able to dephosphorylate tau at several
phosphorylation sites connected to AD pathology (64). Further studies are needed to
better understand if the upregulation of PP5 could be used to slow or prevent tau
pathogenesis.
1.5.2 Hop
The Hsp70-Hsp90 organizing protein, otherwise known as Hop and sometimes
STIP1 (stress inducible protein 1), is involved in helping transfer client proteins from the
early stages of protein maturation involving Hsp70 and Hsp40 to the later stages of the
cycle involving Hsp90 (65). As such, Hop plays a crucial role in the maturation of client
proteins, like tau. A previous study found that when Hop was depleted using siRNA, there
was an accumulation of tau (66). This suggests that Hop is necessary for tau clearance
via Hsp70/Hsp90. In fact, loss-of-function mutations in Hop drive toxic tau accumulation
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in a fly model of tauopathy (67). Together these studies demonstrate a protective role of
Hop in a tauopathic brain.
1.5.3 CHIP
C-terminus of Hsc70-interacting protein (CHIP) is highly involved in the Hsp70Hsp90 machinery acting not only as a co-chaperone, but also as an E3 ubiquitin ligase
responsible for ubiquitin-dependent proteasomal degradation (68). CHIP has many roles
within the cell including stress-response activation, protein triage, and restitution of the
stress response (69). CHIP has been linked to several neurodegenerative disorders
including Huntington’s disease, Parkinson’s disease and AD as well as other diseases
such as cystic fibrosis and cancer (68, 69). In tauopathic mice, CHIP regulates the
removal of tau species that have undergone abnormal phosphorylation and folding (69).
Additionally, silencing CHIP via siRNA, led to a massive increase in tau levels (70).
Similarly, CHIP/Stub1-knockout mice have increased accumulation of phospho- and total
tau species (Table 1.2) (71). Overexpression of CHIP could represent a therapeutic
strategy to prevent neuronal cell death and improve outcomes of neurodegenerative
diseases by promoting the degradation of tau.
1.5.4 DnaJC7
DnaJC7, also known as Tpr2, simultaneously binds Hsp70 and Hsp90 via its two
TPR domains (72). To date, a link between DnaJC7 and tau has not been investigated.
However, it is known that DnaJC7 plays an important role in steroid receptor chaperoning,
as well as recycling substrates from Hsp90 back to Hsp70 via this unique TPR interaction

12

(72, 73). Additional studies are needed to understand if DnaJC7 regulates tau
pathogenesis.
1.5.5 Tom34
Tom34 is a co-chaperone involved in mitochondrial protein import. One study
found that in Drosophila, impaired Tom34 gene function led to enhanced tau pathology
(67). Conversely, the same study demonstrated Tom34 overexpression was able to
suppress tau toxicity elucidating a role for Tom34 in tau pathology in Drosophila. The
mechanism by which Tom34 promotes tau pathology remains unclear. It is possible that
mitochondrial dysfunction could lead to cellular stress which, in turn, could enhance tau
pathology. Additional studies are needed to fully elucidate this interaction.
In addition, there are other TPR-containing Hsp90 co-chaperones such as UNC-45,
Tom70, NASP, SGTA, SGTB, Cns1, CRN, Tah1, TPR1, DYX1C1, and AIPL1. However,
very little is known about most of these co-chaperones in the brain and even less is known
about their interactions with tau, therefore they will not be discussed in detail in this
chapter.
1.6 Non-TPR co-chaperones
1.6.1 Cdc37
Cell division cycle 37 (Cdc37) slows the ATPase activity of Hsp90 allowing a
prolonged interaction between Hsp90 and its client proteins (74). Cdc37 is also required
for the stable folding of protein kinases in coordination with Hsp90 (75). Many of these
kinases are known to phosphorylate tau at sites associated with AD, such as GSK3β and
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MAPK13 (76, 77). Interestingly, overexpression of Cdc37 preserves tau, and its
suppression reduces tau (78). However, additional studies are needed to better
understand the dynamics between Cdc37 and tau phosphorylation.
1.6.2 p23
p23 has an opposing effect on Hsp90 compared to Aha1. p23 works by inhibiting
the ATPase activity of Hsp90. The interaction between Hsp90 and p23 is nucleotidedependent meaning that p23 can only interact with Hsp90 when ATP is bound (79). p23
works in a unique way to inhibit ATPase activity, it can either inhibit the hydrolysis process
or it can impede the release of ADP and Pi (80). As a co-chaperone, p23 works to
suppress protein aggregation and exhibits chaperoning activity, although p23 is not able
to refold proteins on its own (81). Inhibition of p23 in an siRNA screen of Hsp90 cochaperones showed that silencing p23 reduced both total and phospho-tau (66, 78). p23
also plays an important role in preventing endoplasmic reticulum (ER) stress-induced cell
death, which can be triggered by misfolded proteins, like tau (82, 83). However, p23 can
be cleaved during ER stress-induced cell death into a smaller p19 fragment which is then
unable to exert its anti-apoptotic effects (84). A mutant p23 (p23D142N) that is
uncleavable was shown to ameliorate the ER stress-induced cell death in vitro and
suggests that this mutant p23 could be a potential therapeutic target in neurodegenerative
diseases (84).
1.6.3 S100A1
S100 calcium-binding protein A1 (S100A1) interacts with Hsp90. One study used
siRNA to screen several Hsp90 co-chaperones to investigate the effect on tau. This study
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found that reductions in S100A1 also led to massive reductions in both phospho- and total
tau levels in cells (66). S100A1 could play a role in stabilizing tau, thus leading to a
worsening of tau pathology. Therefore, silencing or knocking down S100A1 could offer a
potential therapeutic strategy for tauopathies.
1.6.4 FNIP1
The folliculin-interacting protein 1 (FNIP1) is able to interact with Hsp90 as a cochaperone in order to inhibit its ATPase activity. One study found that FNIP1, in complex
with FNIP2 and Hsp90, was able to stabilize the tumor suppressor folliculin (FLCN; (85)).
FNIP1 was shown to interact directly with Hsp90, and it can also interact with other cochaperones such as p23, Hop and Cdc37 (85). FNIP1 was also shown to compete for
binding with Aha1 suggesting an important role for FNIP1 in the Hsp90 chaperone
network (85). Additional studies are needed to determine if FNIP1 could regulate tau
directly or potentially through competition with Aha1 to bind Hsp90 and alter its ATPase
activity.
1.7 Aging in the Hsp90 Chaperone Network
All of the above mentioned co-chaperones interact with Hsp90 in order to form
diverse heterocomplexes, however, changes in Hsp90 expression with aging can alter
their composition. There is conflicting data on Hsp90 levels with age in both human and
animal studies. One study focused on the basal levels of cytosolic Hsp90 in peripheral
blood mononuclear cells (PBMC) and found that in aged human samples there was an
increase in Hsp90 under normal physiological conditions when compared to young
samples (86). Another study had similar findings in the hippocampus of aged gerbils. This
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study demonstrated that cytosolic Hsp90 levels were significantly increased in the
hippocampus of aged gerbils (24 months) compared to adult gerbils (6 months) (87).
Conversely, there are also studies showing decreased levels of Hsp90 in aged human
brain samples. For instance, two other studies investigated the levels of chaperone
proteins in the human brain. One study found that cytosolic Hsp90 was repressed in the
superior frontal gyrus, while another demonstrated a similar repression in the prefrontal
cortex of aged patients compared to controls (21, 88, 89). Taken together, this data
suggests that alterations in Hsp90 levels do not occur uniformly and that changes in the
expression of Hsp90 with aging may vary between cell types and brain regions (88). While
Hsp90 protein levels are an important factor with aging, co-chaperone expression levels
could be equally important in heterocomplex formation.
In addition to the differences in expression levels of Hsp90, there are also changes
in expression levels of co-chaperone proteins during the aging process. Almost all of the
Hsp90 co-chaperones are repressed in aging, suggesting that these proteins could play
important roles in maintaining homeostasis within the cell (21). For instance, CyP40,
FKBP52, PP5, Hop, p23, and Aha1 are all repressed in the aged brain. All of these
proteins are integral to the Hsp90 chaperone system and when levels of these proteins
go down the Hsp90 chaperone network can no longer function normally, which can lead
to an increased risk of developing a neurodegenerative disease. Interestingly, one cochaperone is significantly induced in the aged brain and that is FKBP51. FKBP51 has
several important roles within the cell including immunoregulation as well as helping with
protein folding and trafficking in complex with Hsp90. Because FKBP51 is induced in
aging, while many other co-chaperones are reduced, this suggests that the imbalance
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seen in these proteins during aging could lead to completely different Hsp90
heterocomplexes resulting in the dysfunction of cellular homeostasis during aging.
Hsp90 is able to form many unique heterocomplexes with different co-chaperones
in order to regulate protein triage. Hsp90 heterocomplexes are unique in that there is
usually a specific progression of co-chaperones that interact with Hsp90 (10). One
interesting aspect to these heterocomplexes is the fact that Hsp90 can bind multiple cochaperones simultaneously. One study found that Hsp90 could form stable complexes
with Hsp90, FKBP52, Hop, and p23 (43). There does appear to be a hierarchy though,
with some co-chaperones able to bind more strongly than others. For example, Aha1 has
been shown to compete with Hop, FNIP1, and p23 for the ability to bind with Hsp90 (42,
85). These competition dynamics between Aha1 and p23/FNIP1 suggest that there is a
constant battle for control of the ATPase activity of Hsp90. Additionally, FKBP51 and
FKBP52 have been shown to have greater relative binding to Hsp90 compared to other
TPR co-chaperones (90). While not as strong as FKBP51 and FKBP52, PP5 forms more
complexes with Hsp90 than most other TPR co-chaperones. Taken together, increased
FKBP51 and decreased PP5 and CyP40 could contribute to an imbalance in Hsp90
heterocomplexes which may promote increased tau phosphorylation and aggregation
causing neurotoxicity (20). This suggests an even more complex system in place because
depending on the amount of certain co-chaperones and their relative ability to bind to
Hsp90; certain maladaptive complexes could be more abundant than others with aging.
In addition to altering Hsp90 heterocomplex composition and client selection,
altered Hsp90 co-chaperone expression can interfere with degradation of aberrant
proteins via the proteasome or autophagy. As mentioned above, aged cells are often
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inundated with misfolded and aggregated proteins, which can overload the Hsp90
chaperone network causing a negative spiral where there are not enough healthy
chaperone molecules to refold or degrade aberrant proteins. In addition to the problems
faced with an overwhelmed chaperone network, the proteolytic activity of the proteasome
also declines with aging, and in fact Hsp90 has been shown to protect the proteasome
from age-related, oxidative-dependent decline (91). However, with advanced aging, the
association between Hsp90 and the proteasome drastically decreases (3). This suggests
that because the Hsp90 chaperone system and the proteasome are so connected, when
one starts to fail the other will fail as well leading to cytotoxicity and cell death. Proteins
can also be degraded by CMA; however, CMA activity also decreases with age (92).
Hsp90 and Hop are both involved in the CMA system; helping to unfold the target
substrate before it can translocate into the lysosome for degradation. As mentioned
previously, both Hsp90 and Hop are repressed in aging and therefore may not be able to
assist in the translocation of substrates, leading to a buildup of misfolded or aggregated
proteins. Post-translational modifications (PTMs) of Hsp90 can also complicate the matter
further.
There are many different PTMs that can affect Hsp90 including phosphorylation,
acetylation, S-nitrosylation, oxidation, and ubiquitination; and all of these PTMs can
impact the chaperoning function of Hsp90. Phosphorylation of Hsp90 leads to reduced
chaperoning ability and phosphorylation of specific tyrosine residues can affect the ability
of Hsp90 to interact with distinct client proteins (93, 94). Acetylation of Hsp90 affects client
protein interaction and also decreases binding of Hsp90 to ATP (93, 95). S-nitrosylation,
oxidation and ubiquitination also inhibit Hsp90 chaperone activity (96–98). These PTMs
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increase with aging and can alter the ability of Hsp90 to function properly as well as
change the ability of different co-chaperones to bind. As the chaperone network declines
with aging, so does the ability of the cell to recover from damaged proteins and stress,
thus leading to an environment which promotes aberrant protein accumulation and
neurotoxicity.
1.8 Targeting the Hsp90 Chaperone Network
Inhibition of the ATPase activity of Hsp90 has been shown to have positive
outcomes in cell culture and animal models of tauopathy. Hsp90 ATPase inhibitors have
been developed to target each of the three domains: N-terminal, middle, and C-terminal;
with the majority of Hsp90 inhibitors targeting the N-terminal domain (99). Inhibition of
Hsp90 induces the expression of protective chaperones, Hsp70 and Hsp40, further
promoting the degradation of aberrant proteins (100). Previous studies have shown that
Hsp90 inhibition decreased the levels of hyperphosphorylated and/or mutated tau species
both in cells and mice. The Hsp90 N-terminal domain inhibitor, EC102, was used to
demonstrate degradation of hyperphosphorylated pathologically relevant tau in cells (15).
Another N-terminal Hsp90 ATPase inhibitor, 17-AAG, was shown to decrease levels of
phosphorylated tau in cells, and a related N-terminal Hsp90 ATPase inhibitor, PU-DZ8,
reduced soluble and insoluble tau in tauP301L mice (16). Although Hsp90 inhibitors have
been in clinical development since 1999, none have reached New Drug Application (NDA)
status (99). All of these clinical trials were focused on investigating Hsp90 inhibitors on
various cancers. Hsp90 plays a similar role in both neurodegenerative disorders and
cancer, however because of the complexity of the brain and the need for a blood-brain
barrier (BBB) permeable drug, the clinical development of Hsp90 inhibitors for
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neurodegenerative diseases has been even less successful. While the development of
Hsp90 inhibitors is still underway, it is possible that the development of therapeutics which
target Hsp90 heterocomplexes or discrete Hsp90 co-chaperones could open up
additional avenues for success in developing a BBB-permeable drug.
In addition to offering more potential therapeutic targets, small molecules which
modify Hsp90/co-chaperone interactions may also show more specificity for a specific
pool of Hsp90 which may reduce the number of on-target side effects. There are very few
Hsp90 co-chaperone targeting small molecules, and of these, only a handful of these
have been investigated for their role in effecting tau. There is a Hop/Hsp90 complex
specific inhibitor, C9, however, there is no available data on how chemical inhibition of
this complex affects tau accumulation (101). The Cdc37/Hsp90 inhibitors, Celasterol and
Withaferin A (102, 103), reduce tau levels and a new compound, platycodin D has just
been discovered (104). Platycodin D does not affect the ATPase activity of Hsp90, but
instead disrupts the interaction between Hsp90 and Cdc37 leading to client protein
degradation without an increase in Hsp70 (104). More work still needs to be done to better
understand the role of Cdc37 in tau phosphorylation to determine if targeting this complex
is of therapeutic benefit. Developing drugs to target discrete FKBPs has been challenging
due to their homology, however, despite their structural similarity they do display
differences in conformational flexibility which could be a way to potentially target specific
FKBPs in the future (105). Interestingly, one study demonstrated that patients chronically
treated with FK506, which inhibits the PPIase domain of many of the FKBPs, significantly
reduced the incidence of AD (106). The targeting FKBP51 is of great interest for the
treatment of tauopathies as well as mood disorders (107). Recently a PPIase antagonist
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has been developed which shows selectivity for FKBP51, but additional studies are
needed to determine if targeting the PPIase domain of FKBP51 will be effective in
regulating tau accumulation (53). There is one compound, MJC13, which targets the
FKBP52-Hsp90-androgen receptor complex (108). MJC13 results in a reduced stress
response which has demonstrated therapeutic potential in cancer, but so far MJC13 has
not been investigated for a role in tau pathology (108). Additionally, Aha1-specific
inhibitors have been recently developed (109). One of these inhibitors, KU-177, reduced
insoluble tauP301L levels in cells (41). While this is an exciting result, more studies are
needed to determine if Aha1 inhibitors regulate tau similarly in vivo. There is still much to
be done to develop compounds which target the Hsp90 chaperone network, but there are
a lot of promising leads which can be targeted to develop disease-modifying therapeutics.
1.9 Conclusions
The Hsp90 chaperone machinery plays a huge role in both aging and
neurodegenerative diseases. Hsp90 is one of the most highly expressed proteins in the
cell and is involved in a myriad of cellular processes. Previous work has focused on
inhibition of Hsp90 to triage misfolded proteins. There are also many co-chaperones that
associate with Hsp90 and play their own roles in aging and neurodegeneration. As these
Hsp90 co-chaperones change with age they can significantly impact the propensity for
certain neurodegenerative diseases. FKBP51 steadily increases with age and both
FKBP51 and Aha1 are induced in the AD brain suggesting that these two co-chaperones
negatively affect tau pathology. On the other hand, both CyP40 and PP5 are repressed
in aged and AD brains. CyP40 disaggregates tau fibrils in vitro and PP5 dephosphorylates
tau restoring microtubule binding, suggesting that increasing the levels or activity of these
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co-chaperones could have a beneficial, neuroprotective role in diseases such as AD.
These are just a few examples of how important maintaining the balance of Hsp90 cochaperones is to homeostasis, and what can happen when they are altered in aging and
disease. Hsp90 co-chaperones offer a unique target for potential therapeutics due to their
specific roles within the Hsp90 machinery. Overall, more work needs to be done to
develop BBB-permeable therapeutics to target discrete Hsp90 co-chaperones for the
treatment of AD and other tauopathies.

Table 1.1 Summary of Hsp90 and Hsp90 co-chaperone levels in aging and
Alzheimer’s disease (AD). A summary of the levels of the Hsp90 chaperone network in
both aging and AD human samples.
Chaperone

Gene

Function

Aging

AD

Reference

Hsp90α

HSP90AA1

Chaperone

Repressed

No Data

Brehme et al., 2014

Hsp90ß

HSP90AB1

Chaperone

Repressed

Repressed

Brehme et al., 2014

CyP40

CYP40

Peptidyl-prolyl
isomerase

Repressed

Repressed

Brehme et al., 2014

FKBP51

FKBP5

Peptidyl-prolyl
isomerase

Induced

Induced

Brehme et al., 2014;
Blair et al., 2013

FKBP52

FKBP4

Peptidyl-prolyl
isomerase

Repressed

Repressed

Brehme et al., 2014;
Meduri et al., 2016

Xap2

AIP

Co-chaperone

Slightly
Repressed

No Data

Brehme et al., 2014

PP5

PPP5

Ser/Thr phosphatase

Repressed

Activity
repressed

Brehme et al., 2014;
Liu et al., 2005

FKBP38

FKBP8

Peptidyl-prolyl
isomerase

Unchanged

No Data

Brehme et al., 2014

FKBP36

FKBP6

Peptidyl-prolyl
isomerase

Unchanged

No Data

Brehme et al., 2014

WISp39

FKBPL

Peptidyl-prolyl
isomerase

Unchanged

Repressed

Brehme et al., 2014
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Table 1.1, Continued
Hop

STIP1

Client protein
maturation

Slightly
Repressed

No Data

Brehme et al., 2014

CHIP

STUB1

E3 ubiquitin ligase

Unchanged

Unchanged

Brehme et al., 2014

DNAJC7

DNAJC7

Steroid receptor cochaperone

Repressed

Repressed

Brehme et al., 2014

Tom34

TOMM34

Mitochondrial import
protein

Unchanged

No Data

Brehme et al., 2014

UNC-45A

UNC45A

Myosin chaperone

Slightly
Induced

Unchanged

Brehme et al., 2014

Tom70

TOMM70

Mitochondrial import
protein

Repressed

Repressed

Brehme et al., 2014;
Loerch et al., 2008

NASP

NASP

Co-chaperone

Slightly
Induced

Induced

Brehme et al., 2014

SGTA

SGTA

Co-chaperone

Unchanged

No Data

Brehme et al., 2014

SGTB

SGTB

Co-chaperone

Repressed

Repressed

Brehme et al., 2014;
Loerch et al., 2008

Cns1

TTC4

Co-chaperone

Induced

No Data

Brehme et al., 2014

CRN

CRNKL1

Co-chaperone

Slightly
Repressed

No Data

Brehme et al., 2014

Tah1

RPAP3

RNA Polymerase IIassociated protein

Repressed

No Data

Brehme et al., 2014

TPR1

TTC1

Co-chaperone

Unchanged

No Data

Brehme et al., 2014

DYX1C1

DNAAF4

Co-chaperone

Induced

No Data

Brehme et al., 2014

AIPL1

AIPL1

Co-chaperone

Unchanged

No Data

Brehme et al., 2014

Cdc37

CDC37

Inhibits ATPase activity

Unchanged

Repressed

Brehme et al., 2014

Aha1

AHSA1

Stimulates ATPase
activity

Slightly
Repressed

Induced

Brehme et al., 2014;
Shelton et al., 2017

p23

PTGES3

Inhibits ATPase activity

Slightly
Repressed

Unchanged

Brehme et al., 2014

S100A1

S100A1

Co-chaperone

No Data

No Data

FNIP1

FNIP1

Co-chaperone

No Data

No Data
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Table 1.2 Summary of Hsp90 and Hsp90 co-chaperone knockout mice. This table
contains information on the available knock-out mouse lines for the Hsp90 chaperone
family.
Protein

Gene

KO model

Viable

Hsp90α

Hsp90aa1

Mouse

Yes

Hsp90β

Hsp90ab1

Mouse

No

Cyp40

Cyp40

Mouse

Yes

Phenotypically normal

Periyasamy et al.
Oncogene 2010

Mouse

Yes

Resilliant to stressinduced depression-like
behavior

Yong et al. JBC 2007;
O'leary et al. PLoS One
2011; Touma et al. Biol
Psychiatry 2011

Reduced fertility in both
males and females

TPR co-chaperones

FKBP51

Fkbp5

Phenotype
Male mice, failure of
spermatogenesis; viable
and phenotypically
normal into adulthood
Early embryonic lethality
(day E9)

Reference
Grad et al. PLoS One
2010
Voss et al. Development
2000

Cheung-Flynn et al. Mol
Endocrin 2005;
Tranguch et al. PNAS
2005; Yang et al. Mol
Endocrin 2006
Raitila et al. Am J Pathol
2010

FKBP52

Fkbp4

Mouse

~50% are
embryonic
lethal

Xap2

AIP

Mouse

No

Embryonic lethality

Yong et al. JBC 2007

PP5

Ppp5

Mouse

Yes

Mice survive both
embryonic development
and into postnatal mice;
defect in DNA damage
checkpoint after ionizing
radiation

FKBP38

Fkbp8

Mouse

No

Embryonically lethal

Bulgakov et al.
Development 2004
Crackower et al. Science
2003

FKBP36

Fkbp6

Mouse

Yes

Both male and female
mice are healthy and live
normal lifespans; male
mice are sterile

WISp39

Fkbpl

Mouse

No

Heterozygous FKBPL
mice appear normal

Hop

Stip1

Mouse

No

CHIP

Stub1

Mouse

Yes

Embryonically lethal
around day E9.5-10.5
Develop normally but
are susceptible to stressinduced apoptosis of
multiple organs;
increased peri- and
postnatal lethality
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Yakkundi et al.
Arterioscler Thromb
Vasc Biol 2015
Beraldo et al FASEB J
2013

Dai et al. EMBO J 2003

Non TPR co-chaperones

Table 1.2, Continued
DnaJC7

Dnajc7

Mouse

Yes

No information on
phenotype

Tom34

TOMM34

Mouse

Yes

Phenotypically normal
Embryonic lethality

Dickinson et al. Nature
2016
Terada et al. J Biochem
2003
Dickinson et al. Nature
2016

UNC45A
Tom70

UNC45A

Mouse

No

TOMM70

No

N/A

NASP

NASP

Mouse

No

Embryonic lethality

Richardson et al. JBC
2006

Less fertile with small
liters and higher
neonatal death rates;
smaller body size in both
males and females

Philp et al. Nature
Scientific Reports 2016

Phenotypically normal

Josefowicz et al. Nature
2012

Tarkar et al. Nat
Genetics 2013

SGTA

SGTA

Mouse

Yes

SGTB

SGTB

No

N/A

Cns1

TTC4

Mouse

Yes

CRN

CRNKL1

No

N/A

Tah1

RPAP3

No

N/A

TPR1

TTC1

No

N/A

DYX1C1

DYX1C1

Mouse

Yes

Embryonic lethality in
approx. 2/3; surviving
mice develop severe
hydrocephalus by
postnatal day 16 and
died by P21

AIPL1

AIPL1

Mouse

Yes

Phenotypically normal

Ramamurthy et al. PNAS
2003

Cdc37

Cdc37

C. elegan

No

Embryonically lethal in C.
elegans

Beers & Kemphues,
Development 2006

Aha1

Ahsa1

Mouse

Yes

No information on
phenotype

The Jackson Laboratory:
Stock No: 029805
Grad et al. Mol and Cell
Biol 2006; Lovgren et al.
Mol and Cell Biol 2007;
Nakatani et al. Biochem
and Biophys Res Comm
2007
Jun Du et al. Mol Cell
Biol 2002
Hasumi et al. PNAS 2015

p23

Ptges3

Mouse

No

Perinatal lethality
resulting from defective
lung development;
Abnormal skin and
reduced expression of
GR markers

S100A1

S100A1

Mouse

Yes

Phenotypically normal

FNIP1

FNIP1

Mouse

Yes

Phenotypically normal
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Figure 1.1. Schematic depicting fate of tau following Hsp90 interaction with
distinct co-chaperones; the impact of Alzheimer’s disease on the levels of cochaperones. Aha1 and FKBP51 protein levels are induced in AD, and their association
to tau leads to increased aggregation. Whereas, CyP40 and PP5 levels are repressed
in AD, and their association to tau leads to reduced tau aggregation. This schematic
highlights the important role of co-chaperones in AD.
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Chapter Two1:
The Hsp90 activator Aha1 drives production of tau aggregates
2.1 Abstract
The microtubule-associated protein tau forms neurotoxic aggregates that promote
cognitive deficits in tauopathies, the most common of which is Alzheimer’s disease (AD).
The 90-kDa heat shock protein (Hsp90) chaperone system affects the accumulation of
these toxic tau species, which can be modulated with Hsp90 inhibitors. However, many
Hsp90 inhibitors are not blood-brain barrier permeable and several present associated
toxicities. Here, we find that the co-chaperone, activator of Hsp90 ATPase homolog 1
(Aha1), dramatically increased the production of aggregated tau. We see that Aha1
overexpression in an iHek-P301L tau model led to the accumulation of insoluble tau.
Whereas, treatment with a novel Aha1 inhibitor, KU-177, dramatically reduced the
accumulation of insoluble tau. Overall, these data demonstrate that Aha1 contributes to
tau fibril formation through Hsp90. This suggests that therapeutics targeting Aha1 may
reduce toxic tau species, which could be beneficial in slowing or preventing the
progression of tauopathies.

____________________
1

Portions of this work were previously published (Shelton LB et al., 2017) and are used with

permission of the publisher.
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2.2 Introduction
The microtubule associated protein tau (MAPT, tau) accumulates and aggregates
in a family of neurodegenerative diseases called tauopathies (110), the most common
being Alzheimer’s disease (111). In particular, the pathogenic formation of oligomeric tau
species is thought to be a major contributor to disease progression (112). One study has
shown that injection of recombinant full-length human tau oligomers in vivo led to synaptic
dysfunction and impaired memory, whereas injection of tau fibrils and monomers did not
(113). Therefore strategies aimed at reducing oligomeric tau accumulation could hold
therapeutic promise for these diseases (114).
Molecular chaperones, including the 90-kDa heat shock protein (Hsp90), regulate
protein folding, degradation, and accumulation (115). Of the proteins regulated by Hsp90,
often referred to as ‘clients,’ tau is one of the most thoroughly characterized (116). In the
past decade, Hsp90 emerged as one of the next breakthrough drug targets for diseases
of aging, particularly for neurodegenerative diseases like tauopathies (117). Small
molecules inhibiting the ATPase activity of Hsp90 showed great promise in preclinical
models, prompting the development of a host of clinical leads (118), but the translation of
this pre-clinical success into patients has been disappointing. Not only have many leads
suffered from poor blood-brain barrier permeability (119), but toxicity has also dampened
enthusiasm (120, 121). This has led to the pursuit of Hsp90 co-chaperones as distinct
drug targets offering an alternative to Hsp90 (115, 122).
Activator of Hsp90 ATPase homolog 1 (Aha1) is the only one of these cochaperones known to stimulate Hsp90 ATPase activity (123). This small 38kDa co-
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chaperone binds to the N-terminal and mid-domains of Hsp90, inducing a partially closed
conformation that accelerates the progression of the ATPase cycle dramatically (123,
124). Therefore, small molecules targeting the interaction of Hsp90 with Aha1 could be
beneficial in disease by reducing Hsp90 ATPase activity (125, 126). Here we sought to
determine if Aha1 could facilitate the pathogenesis of tau by stimulating Hsp90 activity.
We determined that Aha1 stimulation of Hsp90 activity can drive tau fibril formation, in
vitro. Moreover, inhibiting the interaction between Aha1 and Hsp90, using a small
molecule, reduced recombinant tau fibril formation as well as insoluble tau accumulation
in cultured cells. Our findings suggest that targeting Hsp90 co-chaperones may enable
inhibition of tau aggregation, which could re-energize the translational appeal of the
Hsp90 chaperone network as a drug target.
2.3 Materials and Methods
2.3.1 Antibodies
The following antibodies were used: Anti-Aha1 antibodies (StressMarq, SMC-172D and
Abcam, ab83036 for IP), anti-Hsp90 α (StressMarq, SMC-149B), anti-GAPDH
(Proteintech, 60004-1-Ig), H-150 anti-tau (Santa Cruz Biotechnology, sc-5587), and antitau pT231 (Anaspec, 55313-025). PHF1 anti-tau (pS396/404) was a kind gift from Dr.
Peter Davies.
2.3.2 Plasmids and viral vectors
Aha1 WT and Aha1 E67K expression plasmids were generated in our lab using the
pCMV6 backbone.
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2.3.3 Protein expression
Recombinant human P301L tau, Aha1, Aha1 E67K, p23, FKBP51, FKBP52 and CDC37
were cloned into bacterial expression vector, pet28a with a His tag followed by a TEV
sequence. Plasmids were transformed into E.coli (BL21) one-shot star cells and plated
onto kanamycin-agar plates. Plates were grown at 37°C for approximately 16 hours.
10mL LB broth with kanamycin starter cultures were then inoculated with a colony and
the starter culture grown for 8 hours. 1L cultures were then inoculated at 1:100 dilution
and grown to OD600 of 0.8. Cultures were induced with the addition of 1mM IPTG and
the incubator temperature was reduced to 16°C. Cultures were then grown for 14 hours.
Cells were then pelleted at 3,500 x g for 30 minutes and supernatant discarded. Pellets
were resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM Imidazole
with protease inhibitors) and frozen at -80°C. Bacterial pellets were then thawed and lysed
by sonication. Lysates were then spun at 50,000 x g for 1 hr. Next, the supernatant was
purified by nickel affinity chromatography (Nickel Resin, Fisher #PI88222). Protein purity
and expression was then checked by Coomassie stained SDS-PAGE. Next, the protein
was digested with TEV protease, removing the His tag. Finally, proteins were purified by
a size exclusion column (HiLoad 16/600 Superdex200pg). Proteins were then stored at 80°C. Hsp90α protein was a kind gift from Dr. Johannes Buchner.
2.3.4 Transmission Electron Microscopy
10 µL of protein samples were adsorbed onto square mesh copper grids (EMS300-Cu)
for 60 seconds, washed twice with 10 µL of deionized water and excess water removed
by wicking with filter paper. Samples were negatively stained with 1% uranyl acetate for
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30 seconds and dried overnight. Grids were viewed using a JEOL 1400 Digital
Transmission Electron Microscope and images were captured with a Gatan Orius widefield camera. Fields shown are representative.
2.3.5 Thioflavin T fluorescence assay
10 µM P301L tau was incubated with 400 nM of the indicated chaperone in 100 µM
Sodium Acetate pH 7.0 buffer with 2mM DTT, 2.5uM heparin (3,000 Da), and 10uM
Thioflavin ThT in 100 µL volumes in a 96-well black clear-bottom plate (Fisher #07-200525) for 3 days at 37°C. Fluorescence was read at 440 nm excitation and 482 nm
emission in a BioTek Synergy H1 plate reader at indicated time points. All conditions were
performed at least in duplicate.
2.3.6 Cell culture and transfection
iHek-P301L cells (32) and luciferase expressing PC3-MM2 cells (127) were cultured in
DMEM media supplemented with 10% FBS and 1% Penicillin-Streptomycin (Invitrogen).
Inducible cells were incubated with 3 µg of tetracycline for 72 h. 48 h prior to harvest,
transfections were performed with 2.5 μL Lipofectamine 2000 (Invitrogen) per 1 μg of
DNA, which was incubated in serum-free Opti-MEM for 5 minutes before adding the
mixture dropwise to the cells. KU-177 was added 24 h prior to harvest at indicated
concentrations. Cells were harvested in Hsaio TBS buffer (50mM Tris Base, 274mM
NaCl, 5mM KCl, pH 8.0) containing protease inhibitors. Samples were prepared as
previously described (128) to obtain soluble (S1) and Sarkosyl-insoluble (P3) fractions.
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2.3.7 Co-immunoprecipitation
Co-immunoprecipitation of Hsp90α with Aha1 from PC3- MM2 and iHek P301L cells
incubated with the indicated compounds for 24 hours were performed as previously
described (129).
2.3.8 Luciferase refolding assay
Compound dissolved in DMSO at the indicated concentrations or a DMSO control was
evaluated in a luciferase refolding assay in PC3-MM2 cells as previously described (130)
and dose–response curves of the luminescence signal relative to DMSO control were
generated using GraphPad Prism 5.0.
2.3.9 Western blot and dot blot analysis
Cell samples were analyzed by Western blot using 4-15% SDS gradient gels
(BioRad). Antibody dilutions were 1:1000 unless otherwise stated, and all secondary
antibodies were used at 1:1000 (Southern Biotech). Blots were developed using ECL
(Pierce) on a LAS-4000 mini imager (GE Healthcare).
2.3.10 Statistical analysis
To compare two groups, a t-test was used. Groups larger than two were evaluated
using a one-way ANOVA with Dunnett’s multiple comparison test. P values below 0.05
were considered significant.
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2.4 Results
2.4.1 Aha1 enhances Hsp90-dependent tau aggregation.
Since Hsp90 has been shown to exacerbate tau fibril formation (131), we
screened five established Hsp90 co-chaperones to determine whether they had an
inhibitory or stimulatory effect on this process. Recombinant P301L tau was incubated
with Hsp90 in the presence of ATP with or without co-chaperone proteins, as indicated
(Fig. 2.1A). Aha1 was the only co-chaperone to show a significant enhancement of tau
fibril formation; while CDC37, p23, FKBP51 and FKBP52 were not significantly different
than Hsp90 alone. We then examined the effects of Hsp90 and Aha1 on tau fibril
formation over time. We found the most potent inducer of tau fibril formation was Hsp90
and Aha1 combined (Fig. 2.1B). Moreover, Aha1 alone did not affect tau aggregation.
These results were also confirmed using transmission electron microscopy (TEM),
which shows an increase in tau fibrils in the presence of Hsp90, and an exacerbation of
fibrils when both Hsp90 and Aha1 are present (Fig. 2.1C); suggesting that Aha1 could
be responsible for the enhancement of tau aggregates seen. Additionally, a mutant
Aha1-E67K, which does not bind to Hsp90 (Fig. 2.2A), did not enhance tau fibril
formation (Fig. 2.1D). Since heparin is a known tau aggregation inducer, and tau
aggregation can be modulated by DTT, we conducted control experiments to check if
the aggregation behavior of tau can be affected by Hsp90, Aha1, or their combination in
the absence of heparin or DTT. Tau did not fibrillate under these conditions within the
timeframe examined (Fig. 2.3A and B). Moreover, since Aha1 is a known stimulator of
Hsp90 ATPase activity (123, 124), next, we also investigated the effects of these
proteins on tau aggregation in the absence of ATP. We found that ATP was essential
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for Aha1/Hsp90-mediated tau aggregation (Fig. 2.1E). Together, these data indicate
that Aha1 utilizes ATP to enhance Hsp90-mediated tau aggregation.
2.4.2 KU-177 inhibits interaction between Hsp90 and Aha1.
There are no commercially available Aha1-specific inhibitors. We received
novobiocin analogs from Dr. Brian Blagg which were designed to bind to both Hsp90
and Aha1 (KU-174) or to only Aha1 (KU-177, KU-308) (Fig. 2.4A). Immunoprecipitation
of Aha1 from PC3-MM2 cells revealed that Aha1 and Hsp90 complexes were inhibited
by KU-308, KU-177, and KU-174 (Fig. 2.4B). Hsp90-mediated refolding of denatured
luciferase was inhibited with KU-174 (Fig. 2.4C), indicating that this compound directly
inhibits Hsp90, consistent with a previous report (129). However, both KU-308 and KU177, which lack the noviose sugar required for Hsp90 binding (Fig 2.4A, red), did not
inhibit luciferase refolding (Fig. 2.4C). This suggests that these compounds do not
directly inhibit Hsp90, as they were engineered to specifically bind to Aha1. Because of
these characteristics, we chose to use KU-177 as our lead compound. We further tested
the ability of KU-177 to inhibit the interaction between Hsp90 and Aha1 in HEK cells.
Consistent with the PC3-MM2 cells, immunoprecipitation of Aha1 revealed that KU-177
inhibited the binding of Aha1 to Hsp90 (Fig. 2.4D).
2.4.3 KU-177 inhibits tau aggregation in vitro.
We investigated the ability of KU-177 to inhibit Aha1-mediated tau aggregation.
Recombinant P301L tau was incubated with Hsp90 alone or Hsp90 and Aha1, then
treated with KU-177 or DMSO as a control. KU-177 was able to significantly reduce tau
fibril formation compared to the DMSO control (Fig. 2.5A). KU-177 showed a robust
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reduction in tau fibril formation, as observed by TEM (Fig. 2.5B). iHEK-P301L cells
transfected with Aha1-WT or Aha1-E67K were treated with KU-177 and harvested to
examine soluble and Sarkosyl-insoluble tau. We see that both the mutant Aha1-E67K
as well as the Aha1 inhibitor KU-177 were able to reduce insoluble tau (Fig. 2.5C). We
also noted that KU-177 increased soluble, phosphorylated tau however, this finding was
not significant.

2.5 Discussion
In this study we identified the Hsp90 co-chaperone, Aha1, as a potential
therapeutic target for the treatment of tauopathies. Our data suggest that Aha1
increased tau fibril formation resulting in insoluble tau accumulation by stimulating
Hsp90 ATPase activity. Additionally, we demonstrated that the novel Aha1 inhibitor, KU177, reduced the accumulation of insoluble P301L tau in cultured cells. This suggests
that Aha1 may be a promising target for the development of therapeutics directed
toward reducing tau aggregation.
Previous work has focused on Hsp90 as a therapeutic target in order to reduce
the toxic load of amyloidogenic proteins in cells (132). However, this endeavor has been
challenging as Hsp90 has many client proteins within the cell and inhibiting this
chaperone can lead to many pleiotropic effects (120, 133). Compounds that target
specific Hsp90 co-chaperones (122) are being investigated for their potential to be less
toxic as well as more specific (115). Targeting the Hsp90/p23 and Hsp90/CDC37
complexes with celastrol analogs (134–137) or withanolides (138–140) has been
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investigated. However, these compounds still bind Hsp90 and have effects similar to
Hsp90 inhibitors (140, 141). Alternatively, small molecule inhibitors of Hsp90/HOP
complexes disrupt this complex by binding directly to HOP (142). One of these
compounds, C9, was shown to have anticancer effects similar to direct Hsp90 inhibition,
without inducing heat shock response (101). Until recently, there were no known small
molecule inhibitors of Aha1. Ghosh and colleagues identified compounds which bind to
either Hsp90 or Aha1 based on the novobiocin scaffold (129). More recently, two
additional Aha1/Hsp90 inhibitors were identified (143). These compounds demonstrated
protection against pathologies related to cystic fibrosis, but it is still unclear if these
inhibitors bind directly to Hsp90 or Aha1.
Here, we demonstrated that the Aha1-binding inhibitor, KU-177, reduced
Hsp90/Aha1-mediated toxic tau accumulation. Further studies will be required to
determine the pharmacokinetics, brain distribution, and efficacy of KU-177 and future
classes of Aha1 inhibitors. Exploring Aha1 as an alternative to Hsp90 inhibition could reenergize the field, as Aha1 can be targeted more specifically and perhaps avoid the
potential negative side effects that are seen when Hsp90 is inhibited. Additional studies
are also needed to determine the in vivo relevance of this work. Future studies could
investigate the effect of Aha1 knock-down on tau pathology in vivo. Collectively, this study
identified a role for Aha1 in the progression of tauopathies. This suggests inhibition of
Aha1 may prevent the accumulation of pathogenic tau.
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Figure 2.1. Hsp90 and Aha1 synergize to form tau aggregates. (A) Recombinant
P301L tau fibril formation measured by ThT fluorescence, comparing the effect of 5
different recombinant co-chaperone proteins with Hsp90 and ATP (Results represent
the mean ± SEM, n=3; *** = p < 0.001). (B) Recombinant P301L tau fibril formation
measured by ThT fluorescence over a period of 72 hr with or without the addition of
Hsp90 and Aha1 (Results represent the mean ± SEM, n=3). (C) Representative 20,000x
TEM images of recombinant P301L tau fibrils formed in the presence of indicated
chaperone proteins with ATP, scale bar represents 2 µm. (D) Recombinant P301L tau
fibril formation was measured by ThT fluorescence in the presence ATP and
chaperones as indicated (Results represent the mean ± SEM, n=3; * = p<0.05). (E)
Recombinant P301L tau fibril formation measured by ThT fluorescence with varying
mixtures of Hsp90, Aha1 and ATP as indicated (Results represent the mean ± SEM,
n=3; *** = p < 0.001, *p<0.05).
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Figure 2.2. E67K-Aha1 mutation reduces tau aggregation in vitro. (A) Western blot
of immunoprecipitated Hsp90 (FLAG) from iHek cells transfected with either Aha1-WT
or Aha1-E67K.
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Figure 2.3 Tau fibril formation without heparin and DTT. (A) Recombinant P301L
tau fibril formation measured by ThT fluorescence over a period of 72 hr with or without
the addition of Hsp90 and Aha1 (Results represent the mean ± SEM, n=3). (B)
Representative 20,000x TEM images, scale bar represents 2 µm.
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Figure 2.4. KU-177 inhibits interaction between Hsp90 and Aha1. (A) Chemical
structure of the novobiocin analogs KU-174, KU-177 and KU-308. The noviose sugar
moiety (red) is required for Hsp90-binding of novobiocin analogs and is absent in KU177 and KU-308. The biaryl amide moiety (green) has been shown to interact with Aha1
(18). (B) Immunoprecipitated Aha1 from PC3-MM2 cells treated with ± 10 µM KU-308,
KU-177 or KU-174 for 24 hours were analyzed by Western blot. Without antibody (-Ab)
indicates a mock immunoprecipitation. (C) Comparison of Hsp90–mediated luciferase
refolding activity in PC3-MM2 cell treated with DMSO or 100, 25, 6.25, 1.56, 0.39, and
0.097 µM KU-308, KU-177 or KU-174 for 2 hours. IC50 value for KU-177 is shown (R2 =
0.98). Dose response curves for KU-308 and KU-177 suggest the IC50 values would be
higher than the range of concentrations examined here. (KU-308, KU-174 n=3; KU-177
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n=2). (D) Immunoprecipitated Aha1 from iHEK cells treated ± 10 µM KU-177 for 24
hours were analyzed by Western blot.
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Figure 2.5. KU-177 inhibits Aha1 enhancement of Hsp90-mediated tau
aggregation. (A) Recombinant P301L tau fibril formation measured by ThT
fluorescence, comparing the effect of 10 µM KU-177 or DMSO on tau fibril formation
(Results represent the mean ± SEM, n=3; ** = p < 0.01, * = p < 0.05). (B)
Representative 20,000x TEM images of recombinant P301L tau fibrils formed in with
KU-177 or DMSO control, scale bar represents 2 µm. (C) iHek P301L cells transfected
with Aha1-WT, Aha1-E67K or empty vector were treated with 10 µM KU-177 or DMSO
then harvested and soluble and Sarkosyl-insoluble fractions were prepared. Blots were
probed by antibodies as indicated.
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Chapter Three1:
Overexpression of Aha1 accelerates tau pathology and neurotoxicity in rTg4510
mice
3.1 Abstract
Pathological tau aggregates are the hallmark of a group of diseases deemed
tauopathies. Several forms of tau can be seen within the brain, such as tau monomers,
oligomers, and fibrils, with tau oligomers thought to be the most toxic. We previously
demonstrated that Hsp90, together with Aha1, can significantly increase the production
of aggregated tau species in vitro. However, the impact of Hsp90/Aha1 interaction on tau
in vivo has not yet been investigated. Therefore, this study sought to investigate the
effects of Aha1 overexpression in the rTg4510 mouse model of tauopathy. We found that
Aha1 overexpression led to an increased production of both insoluble and oligomeric tau
species in the hippocampi of the mice. Significant cognitive deficits and neuronal loss was
also seen in mice overexpressing Aha1. This suggests that Aha1 overexpression can
induce the formation of pathological tau aggregates. This work provides precedent for the
use of Aha1 as a novel therapeutic target for the treatment of tauopathies.

____________________
1

Portions of this work were previously published (Shelton LB et al., 2017) and are used with

permission of the publisher.
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3.2 Introduction
Tau, a microtubule associated protein, accumulates in many diseases known as
tauopathies, the most common being Alzheimer’s disease (AD). Hyperphosphorylation of
tau allows it to disassociate from the microtubule and leads to its propensity to aggregate
(144). It has been assumed for many years that neurofibrillary tangles (NFTs) were the
cause of toxicity because they correlate well with disease progression (145). However,
more recent evidence suggests that tau oligomers may be the toxic form of tau in
neurodegenerative disease (145). It is plausible that multiple tau conformations can cause
toxicity, but tau oligomers appear to be the most toxic species of tau.
There are several key mutations that occur in tauopathies, which lead to tau
becoming more easily abnormally hyperphosphorylated, including G272V, P301L,
V337M and R406W (146). There are several mouse models that use these mutations to
mimic tauopathies, and to some extent, AD. The P301L mutation has been used to
generate the greatest number of transgenic mouse lines (147). The first mouse line
expressing the P301L mutation was the JNPL3 mice, with 4R/0N (four-repeat, no aminoterminal inserts) under the control of the mouse prion promoter (147, 148). While this
mouse line did develop neurofibrillary tangles in the diencephalon, brainstem and
cerebellar nuclei, there were no clear cognitive deficits or neuronal loss and these mice
had a severe motor impairment (147). Since then, many other mouse lines have been
created expressing the P301L mutation.
The rTg4510 mouse line is another transgenic mouse that expresses the P301L
mutation. Expression of the transgene is driven by a forebrain specific Ca 2+ calmodulin
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kinase II promoter system that results in high levels of expression in the hippocampus
and neocortex (128). An interesting aspect of this mouse line is that transgene expression
is induced via the tetracycline-operon responsive element allowing suppression after
treatment with doxycycline (128). The pathological hallmarks of this mouse model are
striking with an age-dependent accumulation of neurofibrillary tangles (NFT), which can
be seen as early as 2.5 months of age, as well as Sarkosyl-insoluble tau (128, 149).
Additionally, massive neuronal loss can be seen, reaching over 80% loss in the CA1 of
the hippocampus and dentate gyrus by 8.5 months of age (149). Due to this massive
neuronal loss, the rTg4510 mice also display impaired cognition in spatial learning and
memory tasks (128, 150). Astoundingly, tau suppression via doxycycline administration
is able to reverse the cognitive deficits seen, even after accumulation of pathological
NFTs and neuronal loss has occurred (150). Previous work from our lab, has focused on
using co-chaperones, proteins that assist chaperones in protein folding and other
functions, to modulate tau pathology in the rTg4510 mice. FKBP51 and CyP40, while both
immunophilins, have very different effects on tau pathology (49, 131). While FKBP51
increases oligomeric tau and enhanced neurotoxicity, CyP40 had the opposite effect (49,
131). These studies demonstrate that co-chaperones can have different effects on tau
aggregation and provide a precedent for examining the role of Aha1 in this mouse model.
Additionally, Aha1 is the only known stimulator of the ATPase activity of Hsp90, providing
a unique co-chaperone target that, if inhibited, could mimic the effects seen from Hsp90
inhibition (41, 123). Hsp90 inhibition has previously been shown to modulate tau
pathology, however, due to toxicity and bioavailability, Hsp90 inhibitors have not been
successful in clinical populations (15, 18, 19). Therefore, finding a co-chaperone that can
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also modulate tau pathology with more specificity could provide additional therapeutic
targets for the treatment of tauopathies.
For these reasons, we chose to examine the effects of overexpression of Aha1 in
the rTg4510 mouse model. Aha1 was found to be co-localized with tau tangles in AD
brain samples, suggesting that it is a clinically relevant co-chaperone. We also found that
Aha1 overexpression increased both oligomeric and Sarkosyl-insoluble tau in the
hippocampi of the mice. Additionally, we saw increased neuronal loss and cognitive
deficits in mice overexpressing Aha1. Our findings suggest that overexpression of Aha1
in a mouse model of tauopathy significantly worsens the phenotype seen in these mice.
3.3 Materials and Methods
3.3.1 Antibodies
The following antibodies were used: Anti-Aha1 antibodies (StressMarq, SMC-172D and
Abcam, ab83036 for IP), anti-Hsp90 α (StressMarq, SMC-149B), anti-GAPDH
(Proteintech, 60004-1-Ig), anti-NeuN (Millipore, MAB377B), H-150 anti-tau (Santa Cruz
Biotechnology, sc-5587), and anti-tau pT231 (Anaspec, 55313-025). PHF1 anti-tau
(pS396/404) was a kind gift from Dr. Peter Davies. T22 anti-tau oligomer was a kind gift
from Dr. Rakez Kayed.
3.3.2 Plasmids and viral vectors
The Aha1 expression plasmid was generated in our lab using the pCMV6 backbone.
Adeno-associated virus (AAV) serotype 9-Aha1 and AAV9-mCherry were generated in
our lab for murine gene therapy studies.
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3.3.3 Human tissue processing
Brain tissue samples from the medial temporal gyrus of patients with Braak stages 2, 5
or 6 were provided by the University of California Alzheimer’s Disease Research Center
(UCI-ADRC) and the Institute for Memory Impairments and Neurological Disorders.
Samples were fixed in 4% paraformaldehyde overnight, then sucrose gradients up to
30% were used and tissue was sectioned on a sliding microtome at 25 µm thick
sections. Sections were stored at 4ºC in Dulbecco’s phosphate buffered saline (PBS)
supplemented with 0.065% sodium azide until they were used for
immunohistochemistry.
3.3.4 Animal studies and tissue processing
rTg4510 (Jackson labs) and non-transgenic control mice received bilateral stereotaxic
hippocampal (X = ±3.6, Y = -3.5, Z = +2.68) injections of AAV9 vector (Mini CMV +
CBA) (1012) at 5-months old. (N = 20 [10 transgenic; 7 male, 3 female], [10 nontransgenic; 7 male, 3 female] for Aha1. N = 19 [9 transgenic; 6 male, 3 female], [10 nontransgenic; 6 male, 4 female] for mCherry). Each injection delivered 2 μL of AAV9
particles. At 7-months of age the mice were used for behavioral testing using the radial
arm water maze (RAWM) task. Upon completion of RAWM the brains were harvested
after cardiac perfusion with 0.9% saline. The right hemisphere from each mouse was
dissected and hippocampus was then snap frozen and stored at -80°C until processed
as previously described (128) to obtain soluble (S1) and Sarkosyl-insoluble (P3)
fractions. The left hemisphere from each mouse was fixed in 4% paraformaldehyde
overnight, then sucrose gradients up to 30% were used and 25 µm thick tissue sections
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were generated using a sliding microtome for general histochemical staining, and 50 µm
sections for stereology studies. Sections were stored at 4ºC in Dulbecco’s phosphate
buffered saline (PBS) supplemented with 0.065% sodium azide until they were used for
immunohistochemistry.
3.3.5 Western blot and dot blot analysis
Mouse brain tissue samples were analyzed by Western blot using 4-15% SDS gradient
gels (BioRad). Antibody dilutions were 1:1000 unless otherwise stated, and all
secondary antibodies were used at 1:1000 (Southern Biotech). Blots were developed
using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare). For dot blots, proteins
were applied onto a wet nitrocellulose membrane and dried by vacuum. Dried
membranes were blocked and developed as described above.
3.3.6 Semi-denaturing Western blot
Tissue was homogenized using sonication and the low-speed spin fraction was
collected after centrifugation at 13,000xg for 15 min. Samples were then mixed with 2X
Laemmli sample buffer (BioRad) containing 2.1% SDS, and run on a blot using 4-15%
SDS gradient gels (BioRad) without boiling the samples or adding β-Mercaptoethanol
(βME).
3.3.7 Radial arm water maze
The radial arm water maze (RAWM) was performed as previously described (151).
Briefly, a circular black tank with a six arm metal insert was filled with water and a
platform was submerged 1 cm below the surface of the water at the end of a designated
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goal arm. Animals were permitted 60 seconds to locate the platform, during which time
an observer blind to treatment manually scored the number of errors. An error was
defined as an entry into an incorrect arm or the absence of an arm choice within 15
seconds. Mice were trained over 2 days with 12 trials per day, which were divided into 4
blocks of 3 trials each. Average errors were calculated for each mouse on day 1 and
day 2. Groups were evaluated separately for each day with a one-way ANOVA using a
Least Significant Difference test to compare groups.
3.3.8 Immunohistochemistry
All immunohistochemistry was done using free floating sections as previously described
(152). Briefly, sections were incubated in PBS with 10% MeOH and 3% H 2O2 to block
endogenous peroxidases. After PBS washes, tissue was permeabilized for 30 minutes
by 0.2% Triton X-100 with 1.83% lysine and 4% serum in PBS. Following
permeabilization, tissue was incubated overnight, at room temperature with either antiAha1 (rat, 1:7000), or anti-T22 (rabbit, 1:700). Following PBS washes, biotinylated goat
anti-rat (1:1000) or goat anti-rabbit (1:3000) secondary antibody was added for 2 hours.
An ABC kit (Vectastain) was used to increase visibility. Following three PBS washes,
tissue was incubated with 0.05% diaminobenzidine plus 0.5% nickel and developed with
0.03% H2O2. Sections were then mounted on charged slides, allowed to dry overnight
and dehydrated in alcohol gradients. Slides were coverslipped with DPX following
clearing with Histoclear (National Diagnostics).
Human tissue was stained as previously described using immunofluorescent secondary
antibodies (131, 153). Briefly, the tissue was permeabilized as described above and
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incubated at room temperature overnight with rat anti-Aha1 (1:100), and mouse antiPHF1 (1:100). Following washes sections were incubated for 2 hours with AlexaFluor488-labelled goat anti-rat (1:1000) or AlexaFluor 594-labelled goat anti-mouse (1:1000)
secondary antibodies. Following secondary incubation, sections were stained with
Neurotrace (1:25) (Invitrogen) for 20 minutes. Human tissue was also incubated in 0.1%
Sudan Black B in 70% EtOH (Sigma) to reduce autofluorescence for 20 minutes and
then washed three times with 0.2% Tween in PBS following fluorescent secondary.
Tissue was mounted after three washes and coverslipped with ProLong Gold antifade
(Invitrogen) reagent.
Sections stained for stereology were blocked and permeabilized as described above
and incubated overnight at room temperature with biotinylated anti-NeuN (1:3000).
Following washes, ABC conjugation, and peroxidase development, tissue was mounted
on charged glass slides and allowed to dry overnight. A 0.05% cresyl violet counterstain
was applied to slides then briefly and quickly destained with 0.3% acetic acid in water
prior to dehydration.
3.3.9 Microscopy
Brightfield stained tissue was imaged using a Plan-Apochromat20x/0.88 objective on a
Zeiss Axioscan.Z1 slide scanner. Brain tissue immunofluorescently stained was imaged
using the Leica TCS SP2 for image analysis. The Zeiss LSM 880 AxioObserver laser
scanning confocal microscope was used for representative images. Fields of view were
selected in the cortex based on tau positive staining. A 63x/1.40PLAN APO Oil
objective was used to take a minimum of 10 1 μm Z-stacked images with Argon (for tau-
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positive signal in green), and Red HeNe (for Aha1-positive and Neurotrace signal in
red).
3.3.10 Imaging analysis
Brightfield image analysis was performed using NearCYTE software
(http://www.nearcyte.org) as previously described (131). This program was used to
outline regions of interest and then thresholds were set manually until all of the userdetermined positive cells were selected with as little non-specific area selected as
possible. Using the batch process option, the area positive ratio was automatically
calculated for each slide.
Fluorescent image analysis was performed using ImageJ. Background was subtracted
from the red channel using the Gaussian Blur tool (Radius = 50um) and then the new
blurred image was subtracted from the original image. The red channel was also
despeckled before image analysis. Both channels were set to a consistent threshold
and then colocalization between the red and green channels were quantified with a
Pearson’s coefficient. The intensity of red fluorescence was also measured in order to
make a scatter plot showing levels of Aha1 in relation to Braak staging.
3.3.11 Stereology
Neurons were stained with anti-NeuN and cresyl violet, and those positive for both were
counted in the CA1 of the hippocampus. A computerized stereological system,
connected to a Leica DM4000B microscope with a Prior motorized stage, was used to
outline the area using distinct landmarks in the brain at 4x magnification (153, 154).
Every 8th section was sliced at 50um to be used for stereology, and only sections
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containing hippocampi (as determined by analyzer) were counted (mCherry N = 7
animals, ~9 sections/animal, ~5 reference points/section; Aha1 N= 8, ~9
sections/animal, ~5 reference points/section). After the initial analysis, the mCherry
control group was reanalyzed at a higher stringency level. Neurons were counted in this
region by using randomly designated areas in the computer generated grid using a 100x
oil immersion lens. Neurons were counted when they were located within the threedimensional dissectors or touching the inclusion lines, and the top and bottom 1 µm of
tissue were excluded. After analysis of all tissue, the number of neurons/animal were
multiplied by 4.5 in order to reflect the total number of neurons throughout the
hippocampus.
3.3.12 Statistical analysis
To compare two groups, a t-test was used. Groups larger than two were evaluated
using a one-way ANOVA with Dunnett’s multiple comparison test. P values below 0.05
were considered significant.
3.3.13 Study approval
All studies were carried out following the guidelines set by the University of South
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care International
(AALAC) regulations. All human tissue was acquired under approved Institutional
Review Board (IRB) protocols for the University of California, Irvine. Patient samples
were deidentified and approved for studies of this nature with written informed consent
to use the tissue for research purposes.
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3.4 Results
3.4.1 Aha1 co-localization with tau tangles correlates with disease progression in human
AD brain.
Our previous work has shown that Aha1 overexpression led to increased insoluble
tau in cell models. However, the relevance of this finding in vivo and more importantly, in
a clinical population, was not clear. Therefore, we evaluated post-mortem human brain
samples from patients with AD or healthy age-matched controls for Aha1 localization in
relation to tau tangles (Fig. 3.1A). We found a significant increase in the amount of colocalization between Aha1 and tau tangles as shown by immunofluorescence
(pS396/404, PHF1) in AD samples compared to control (Fig. 3.1B). Additionally, there
was a positive correlation between Aha1 immunofluorescence intensity and tau Braak
staging (Fig. 3.1C). This suggests Aha1 is involved in pathological tau progression
providing clinical significance for Aha1 in tauopathies such as AD. These findings provide
a clear rationale for investigating the link between Aha1 and tau pathology.
3.4.2 Aha1 overexpression in rTg4510 mice increased insoluble tau species.
In order to investigate the role of Aha1 in vivo, five-month old rTg4510 mice
received bilateral hippocampal injections of AAV9-Aha1 (n = 9) or AAV9-mCherry (n = 8)
(Fig. 3.2A). Immunohistochemical staining revealed that Aha1 was overexpressed
throughout the hippocampus, suggesting a robust effect of the virus (Fig. 3.2B). After
confirming viral expression throughout the hippocampus, the right hippocampi was used
for biochemical analysis of several tau species, including Sarkosyl-insoluble tau. Aha1
overexpression significantly increased total monomeric and multimeric Sarkosyl-insoluble
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tau in the hippocampus (Fig. 3.3A and B). Two different phosphorylated tau species
(pS396/404 and pT231) were also examined, however, no significant differences were
detected suggesting that Aha1 overexpression does not affect these specific
phosphorylated tau species (Fig. 3.3C and D). Additionally, Sarkosyl-insoluble tau was
not detected in wild-type mice, however there was a modest increase in soluble tau
species in wild-type mice overexpressing Aha1, suggesting that Aha1 could interact with
soluble, wild-type tau (Fig. 3.4A).
3.4.3 In vivo, Aha1 overexpression increases toxic tau oligomers
In addition to the increased insoluble tau, Aha1 overexpression also increased
toxic T22-tau oligomer levels (131). Low-speed spin lysate taken from both individual
mouse samples (Fig. 3.5A and B) as well as in pooled samples from each treatment group
were run on a dot blot to check T22-tau oligomer levels (Fig. 3.5C and D). Both the
individual samples, as well as the pooled samples show an increase in oligomeric tau.
This increase of T22-tau oligomers in Aha1 overexpressing mice was further confirmed
using immunohistochemistry, where free floating sections from the left hippocampi were
stained with T22 antibody (Fig. 3.5E and F). Additionally, a semi-denaturing Western blot
was run and again we show that Aha1 overexpressing mice have significantly increased
T22-tau oligomers (Fig. 3.5G and H).
3.4.4 Aha1 overexpression in rTg4510 mice leads to neuronal loss and cognitive
impairments.
Using unbiased stereology, rTg4510 mice overexpressing Aha1 showed a
significant reduction in hippocampal CA1 neurons compared to mCherry controls (Fig.
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3.6A and B). This suggests that Aha1 overexpression enhances neuronal loss in the
rTg4510 mice. Learning and memory were evaluated in AAV9-Aha1 (n=9) and AAV9mCherry (n=8) injected mice using the two-day radial arm water maze (RAWM). The
RAWM is a spatial learning and memory task that evaluates both working and reference
memory (151, 155). Animals overexpressing Aha1 made significantly more errors in
locating the submerged escape platform compared to mCherry overexpressing
littermates, demonstrating a memory recall deficit (Fig. 3.6C). This suggests that the
enhanced neurotoxicity seen in the mice overexpressing Aha1 is significant enough to
affect learning and memory as well. Overall, these data demonstrate that Aha1 enhances
Hsp90-mediated tau aggregation and this interaction results in increased oligomeric and
insoluble tau concomitant with neuronal loss and memory deficits.

3.5 Discussion
Here, we have demonstrated that overexpression of the co-chaperone Aha1 leads
to a significant increase of pathological tau in the rTg4510 mouse model. We also
identified the clinical relevance of Aha1, identifying that there is an increase in Aha1 levels
and Aha1 is more highly co-localized with tau tangles in AD brain tissue. Taken together,
this work demonstrates the importance of focusing on Aha1 as a therapeutic target for
tauopathies.
Our previous work has focused on the impact of Aha1 overexpression on tau
pathology in vitro so it was important to demonstrate that this finding would translate in
vivo as well. Several other Hsp90 co-chaperones have also been shown to affect tau
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pathology. For instance, FKBP51 has also been shown to increase oligomeric tau in the
rTg4510 mouse model (131). Another immunophilin, FKBP52, was shown to bind directly
to P301L tau and induce oligomer formation (156). Additionally, overexpression of the cochaperone Cdc37 has been shown to preserve phosphorylated tau in vitro (157). There
is also one co-chaperone that has been shown to promote the degradation of tau in vivo.
The immunophilin, CyP40, has been shown to reduce the amount of oligomeric tau and
preserve neurons in rTg4510 mice (49). While there are many co-chaperones that can
affect tau pathology, both negatively and positively, Aha1 is a unique therapeutic target
because of how it affects Hsp90. As mentioned in previous chapters, Aha1 is the only
known stimulator of the ATPase activity of Hsp90. This means that using an inhibitor to
target Aha1 may have a similar effect to using an Hsp90 inhibitor.
This work has shown that Aha1 overexpression led to an increase in both
oligomeric and insoluble tau levels in vivo, and this increase in pathological tau
manifested in cognitive deficits and neuronal loss. With this information, future studies
could investigate the potential therapeutic effects of Aha1 inhibition on tau pathology in
vivo.
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Figure 3.1. Human AD samples show co-localization between Aha1 and tau
tangles. (A) Tissue samples from the medial temporal gyrus of patients at Braak stage
2, 5 or 6 were stained for Aha1 (Red), pS396/404 tau tangles (Green) and neuronal
nissl (Neurotrace, Blue) and imaged using confocal microscopy, images taken at 60x.
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Scale bar represents 20 µm. Representative no primary sections from a Braak stage 6
sample are shown. . (B) Quantification of co-localization between Aha1 and
phosphorylated tau tangles (pS396/404) (Results represent the mean Pearson’s
correlation coefficient ± SEM, n=10 images; *** = p<0.001). (C) Scatter plot of the
intensity of Aha1 fluorescence and Braak staging (Results represent the mean
fluorescence intensity ± SEM; Braak stage 2: n=10 images, Braak stage 5: n=14
images, Braak stage 6: n=9 images; *** = p<0.001).
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Figure 3.2. Viral transduction leads to sustained overexpression of Aha1 in the
hippocampus of rTg4510 mice. (A) Characteristic phenotype of rTg4510 tau
transgenic mouse model along with experimental design time points. (B) Representative
images of brain sections showing viral expression of Aha1 protein in AAV9 injected
Aha1 and mCherry control littermates. Scale bars represent 1000 µm for the whole slice
and 250 µm for the inset.
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Figure 3.3. Aha1 overexpression in rTg4510 mice leads to increases in insoluble
tau species. (A) Western blot analysis of soluble and Sarkosyl-insoluble fractions from
hippocampal tissue of rTg4510 mice expressing either AAV9-Aha1 or AAV9-mCherry.
Six representative samples from AAV9-Aha1 and AAV9-mCherry injected mice are
shown. (B) Quantification of Western blots of Sarkosyl-insoluble total (aa 1-150),
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pS396/404 and pT231 tau (Results represent the mean ± SEM relative to the level of
monomeric tau in AAV9-mCherry injected mice; mCherry, n=8; Aha1, n=9; * = p < 0.05,
** = p<0.01).
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Figure 3.4. Tau solubility in wild-type mice. (A) Western blot analysis of soluble and
Sarkosyl-insoluble fractions from hippocampal tissue of wild-type mice expressing either
AAV9-Aha1 (n=7) or AAV9-mCherry (n=8). One rTg4510 mouse sample was included
as a comparison.
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Figure 3.5. Aha1 overexpression in rTg4510 mice leads to increases in
pathological tau species. (A) Dot blot of hippocampal tissue of individual mice shown
in triplicate probed by T22. (B) Quantification of dot blot (Results represent the mean ±
SEM; mCherry, n=8; Aha1, n=8; **p < 0.01). (C) Dot blot of pooled hippocampal tissue
shown in triplicate probed by T22. (D) Quantification of dot blot (Results represent the
mean ± SEM of triplicate samples taken from the pooled fractions; n=3; * = p < 0.05).
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(E) Representative images of brain tissue slices stained with T22 from AAV9-mCherry
and AAV9-Aha1 injected mice. Scale bars represent 1000 µm for the whole slice and
250 µm for the inset. (F) Quantification of the T22 positive area in the hippocampal field
of view (inset from E) (Results represent the mean ± SEM; mCherry, n=8; Aha1, n=9; *p
< 0.05). (G) Samples from AAV9-Aha1 and AAV9-mCherry mice were run on a semidenaturing gel and probed by T22 (1:500) along with other antibodies as indicated. (H)
Quantification of T22 Western blot (~75 kDa, results represent the mean ± SEM;
mCherry, n=6; Aha1, n=7).
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Figure 3.6. Aha1 overexpression in rTg4510 mice leads to cognitive impairments.
(A) Representative images of NeuN stained neurons in the CA1 region of the
hippocampus (brown) counter stained with cresyl violet (purple) from AAV9-mCherry and
AAV9-Aha1 injected mice. Inset scale bars represent 100 µm. (B) Quantification of
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unbiased stereology (Results represent the mean ± SEM; mCherry, n=7; Aha1, n=8; p =
0.0003). (C) Radial arm water maze (RAWM) was performed on AAV9-Aha1 and AAV9mCherry rTg4510 (Tg) and wild-type (WT) littermates as indicated. Average errors from
Day 1 (training) and Day 2 (memory) are shown. (Results represent the mean ± SEM;
n≥9; * = p < 0.05).
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Chapter Four:
Aha1 knock-down results in reduced tau pathology and neuroprotection in
rTg4510 mice

4.1 Abstract
The Hsp90 chaperone network has been studied for its role in tauopathies for
some time. Many Hsp90/co-chaperone complexes have been implicated for their role,
both positive and negative, in tau pathology. For example, the FKBP51/Hsp90 complex
can worsen tau pathology, while the CyP40/Hsp90 complex is able to disaggregate tau
fibrils and rescue neurotoxicity in vivo. Recently, the co-chaperone Aha1, in complex
with Hsp90, was shown to worsen tau pathology in rTg4510 mice providing another cochaperone complex to potentially target. In this study, we have shown that pathological
tau levels are reduced when Aha1 is knocked-down in the rTg4510 mouse model.
Additionally, Aha1 knock-down preserves neuronal loss in the CA1 of the hippocampus.
Our data support the role of the Aha1/Hsp90 complex in tau pathology and provide
additional support of this complex as a target to treat tauopathies.

4.2 Introduction
Current therapeutics for the treatment of tauopathies are very limited and focus
only on the symptoms of the disease (158). Disease-modifying treatments for
tauopathies are sorely needed but so far these treatments have failed in clinical trials
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(159). Hsp90 inhibitors were thought to be a possible candidate for treating tauopathies
but have shown toxicities in clinical populations (17). Since then, some researchers
have switched to focus on targeting Hsp90 co-chaperones instead, with the hope of
more specificity and less toxicity. Previous work focusing on co-chaperones of Hsp90
have also shown promise in reducing toxic tau species but so far none have been
successful in transitioning to the clinic (101–104). The co-chaperone Aha1 is a relatively
novel co-chaperone in the field of tauopathies and because of its stimulatory function on
the ATPase activity of Hsp90, Aha1 offers a unique therapeutic target (41).
While Aha1 is a novel target in the field of tauopathies, it has been studied for its
role in both cancer and cystic fibrosis in the past. Inhibition of Aha1 has been found to
be beneficial in both cancer and cystic fibrosis and previous work from our lab found
that overexpression of Aha1 is detrimental in tauopathy (38, 41, 126). Therefore,
developing a therapeutic that targets Aha1 could be advantageous in multiple diseases.
Previous work has used both genetic inhibition, as well as novel Aha1 inhibitors. One
group has shown that gene silencing of Aha1 via siRNA led to a rescue of misfolded
CFTR in cystic fibrosis (126). Other work has focused on screening novel compounds to
be used as Aha1 inhibitors in the treatment of both cancer and cystic fibrosis (143, 160).
Here we sought to knock-down Aha1 in vivo using shRNA packaged inside
adeno-associated virus serotype 9 (AAV9). We found that Aha1 was knocked-down in
the rTg4510 mice, and the reduced levels of Aha1 resulted in decreased, pathologically
relevant tau species. Additionally, Aha1 knock-down resulted in a preservation of
neurons in the CA1 of the hippocampus. Our findings suggest that knock-down of Aha1
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is a potential target for the treatment of tauopathies because of the reductions in
pathological tau accumulation as well as the neuroprotective effects seen.
4.3 Materials and methods
4.3.1 Materials
Antibodies: Anti-Aha1 (StressMarq, SMC-172D), anti-GAPDH (Proteintech, 60004-1-Ig),
anti-NeuN (Millipore, MAB377B), H-150 anti-tau (Santa Cruz Biotechnology, sc-5587),
anti-total human tau (Dako, A0024). PHF1 anti-tau (pS396/404) was a kind gift from Dr.
Peter Davies. T22 anti-tau oligomer was a kind gift from Dr. Rakez Kayed.
Plasmids: The shRNA-Aha1 and shRNA-scrambled plasmids were ordered from Sigma.
4.3.2 Cell culture and transfection
N2A cells were cultured in MEM media supplemented with 10% FBS and 1% PenicillinStreptomycin (Invitrogen). Transfections were performed with 2.5 μL Lipofectamine
2000 (Invitrogen) per 1 μg of DNA, which was incubated in serum-free Opti-MEM for 5
minutes before adding the mixture dropwise to the cells. Cells were harvested in RIPA
buffer (10 mM Tris-Cl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1%
SDS, 140 mM NaCl, pH 7.4) containing protease inhibitors.
4.3.3 Viral vector production
Adeno-associated virus (AAV) serotype 9-shRNA-Aha1 and AAV9-shRNA-scrambled
were generated in our lab for murine gene therapy studies. The shRNA-Aha1
(CCGGCAACAGGAAAGGCAAACTTATCTCGAGATAAGTTTGCCTTTCCTGTTGTTTT
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TG) and shRNA-scrambled were placed in a pTR12.1 backbone with a U6 promoter,
followed by a chicken-β-actin (CBA) promoter and mCherry to observe viral expression.
4.3.4 Western blot and dot blot analysis
Cell and mouse brain samples were analyzed by Western blot using 4-15% SDS
gradient gels (BioRad). Antibody dilutions were 1:1000 unless otherwise stated and all
secondary antibodies were used at 1:1000 (Southern Biotech). Blots were developed
using ECL (Pierce) on a LAS-4000 mini imager (GE Healthcare). For dot blots, proteins
were applied onto a wet nitrocellulose membrane and dried by vacuum. Dried
membranes were blocked and developed as described above.
4.3.5 Immunohistochemistry
All immunohistochemistry was done using free floating sections as previously described
(152). Briefly, sections were incubated in PBS with 10% MeOH and 3% H 2O2 to block
endogenous peroxidases. After PBS washes, tissue was permeabilized for 30 minutes
by 0.2% Triton X-100 with 1.83% lysine and 4% serum in PBS. Following
permeabilization, tissue was incubated overnight, at room temperature with either antiPHF1 (mouse, 1:5000), or anti-total human tau (rabbit, 1:100000). Following PBS
washes, biotinylated goat anti-mouse (1:3000) or goat anti-rabbit (1:3000) secondary
antibody was added for 2 hours. An ABC kit (Vectastain) was used to increase visibility.
Following three PBS washes, tissue was incubated with 0.05% diaminobenzidine plus
0.5% nickel and developed with 0.03% H2O2. Sections were then mounted on charged
slides, allowed to dry overnight and dehydrated in alcohol gradients. Slides were
coverslipped with DPX following clearing with Histoclear (National Diagnostics). Gallyas
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silver stain was performed as previously described for non-paraffin imbedded tissue
(148).
Mouse tissue was also stained immunofluorescently as previously described (131, 153).
Briefly, the tissue was permeabilized as described above and incubated at room
temperature overnight with rat anti-Aha1 (1:100). Following washes sections were
incubated for 2 hours with AlexaFluor-647-labelled goat anti-rat (1:1000) secondary
antibody. Tissue was then mounted after three washes and coverslipped with ProLong
Gold antifade (Invitrogen) reagent.
Sections stained for stereology were blocked and permeabilized as described above
and incubated overnight at room temperature with biotinylated anti-NeuN (1:3000).
Following washes, ABC conjugation, and peroxidase development, tissue was mounted
on charged glass slides and allowed to dry overnight. A 0.05% cresyl violet counterstain
was applied to slides then briefly and quickly destained with 0.3% acetic acid in water
prior to dehydration.
4.3.6 Microscopy
Both brightfield and fluorescently stained tissue was imaged using a PlanApochromat20x/0.88 objective on a Zeiss Axioscan.Z1 slide scanner.
4.3.7 Imaging analysis
Brightfield and fluorescent image analysis was performed using NearCYTE software
(http://www.nearcyte.org) as previously described (131). This program was used to
outline regions of interest and then thresholds were set manually until all of the userdetermined positive cells were selected with as little non-specific area selected as
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possible. Using the batch process option, the area positive ratio was automatically
calculated for each slide.
4.3.8 Stereology
Neurons were stained with anti-NeuN and cresyl violet, and those positive for both were
counted in the CA1 of the hippocampus. A computerized stereological system,
connected to a Leica DM4000B microscope with a Prior motorized stage, was used to
outline the area using distinct landmarks in the brain at 4x magnification (153, 154).
Every 8th section was sliced at 50um to be used for stereology, and only sections
containing hippocampi (as determined by analyzer) were counted. Neurons were
counted in this region by using randomly designated areas in the computer generated
grid using a 100x oil immersion lens. Neurons were counted when they were located
within the three-dimensional dissectors or touching the inclusion lines, and the top and
bottom 1 µm of tissue were excluded. After analysis of all tissue, the number of
neurons/animal were multiplied by 4.5 in order to reflect the total number of neurons
throughout the hippocampus.
4.3.9 Statistical analysis
To compare two groups, a t-test was used. Groups larger than two were evaluated
using a one-way ANOVA with Dunnett’s multiple comparison test. P values below 0.05
were considered significant.
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4.3.10 Study approval
All studies were carried out following the guidelines set by the University of South
Florida’s Institutional Animal Care and Use Committee (IACUC) in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care International
(AALAC) regulations.

4.4 Results
4.4.1 Developing an shRNA-Aha1 AAV9 virus
Several mouse shRNA-Aha1 plasmids were tested for knock-down efficiency in
N2A cells because of the high levels of endogenous Aha1 (Fig. 4.1A). All three shRNA
plasmids were able to reduce the levels of Aha1 compared to control, however shAha13 led to the greatest reductions so we chose to move forward with that plasmid (Fig.
4.1B). From there, both the shRNA-Aha1 and shRNA scramble, as our control virus,
were inserted into an AAV9 viral vector along with mCherry on a separate promoter to
verify viral expression (Fig. 4.1C).
4.4.2 Knock-down of Aha1 is confirmed after three months of expression
Five-month-old rTg4510 mice received bilateral hippocampal injections of AAV9shRNA-Aha1 (shAha1, n=8) or AAV9-shRNA-scrambled (scrambled, n=10), with three
months of viral expression. Aha1 knock-down was confirmed both with Western blot
(Fig. 4.2A and B) as well as with immunofluorescence (Fig. 4.2C and D), showing that
both the left and right hippocampi had a significant reduction in Aha1 levels.
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4.4.3 Aha1 knock-down in rTg4510 mice decreased pathological tau species and
reduced neurotoxicity.
Our previous work has shown that knock-down of Aha1 prevents insoluble tau
accumulation in vitro so we chose to stain for Gallyas-silver positive tangles, which are
a traditional pathological hallmark of AD and other tauopathies (41). The rTg4510 mice
are a good model to use because they are one of the only transgenic models that
produce Gallyas-silver positive tangles. We found that in our shAha1 mice, there was a
significant reduction in the amount of Gallyas-silver positive tangles (Fig. 4.3A and B).
After seeing a reduction in pathologically relevant tau species, we wanted to look at
whether Aha1 knock-down affected neurotoxicity. Using unbiased stereology, neurons
from the CA1 of the hippocampus were counted. Aha1 knock-down led to a complete
rescue of hippocampal CA1 neurons (Fig 4.4A and B).
4.4.4 Aha1 knock-down reduced phosphorylated but not total or oligomeric tau
We also wanted to examine other tau species to see if shAha1 has an effect on
oligomeric, phosphorylated, or total tau. We found that knock-down of Aha1 led to
reductions in phosphorylated tau (Fig. 4.5A-D), but did not result in reductions of total
tau (Fig. 4.6A and B). We also examined oligomeric tau species via both
immunohistochemistry (Fig. 4.7A and B) as well as biochemically (Fig. 4.7C and D). We
did not see a significant difference in oligomeric tau species between scrambled and
shAha1 mice.

75

4.5 Discussion
Here we show that Aha1 knock-down led to reductions in both phosphorylated
and Gallyas silver positive tau tangles. In addition to less pathological tau species, we
also found that Aha1 knock-down resulted in preservation of neurons in the CA1 of the
hippocampus of rTg4510 mice. These findings suggest that Aha1 knock-down could
potentially slow the progression of tauopathies, as the mice were injected at 5 months of
age and they did not develop accumulation of pathological tau or neuronal loss at the
severity that is typically seen in these mice by 8 months of age. While we did not see a
difference in oligomeric tau in these mice, that could be due to a lack of robust Aha1
knock-down or it could also be a timing issue as we only examined the pathological tau
accumulation at one time point. Oligomeric tau could be harder to degrade or take
longer to degrade than other tau species which could explain the discrepancies seen
between Aha1 overexpression and knock-down.
Previous work has also revealed the benefit of inhibiting Aha1, as this results in
less Hsp90 ATPase activity, which can be beneficial especially in cancer cells. By
reducing the ATPase activity of Hsp90, cancerous cells become more responsive to
treatment (38). The same could be true for tauopathies as well. If the ATPase cycle of
Hsp90 is slowed, it could allow more time for Hsp90 to properly deal with aggregated
tau, allowing the preservation of neurons. Alternatively, Hsp90 could be holding tau in
its aggregated state because it is not able to properly refold it and if Aha1 levels are
reduced this could prevent Hsp90 from attempting to refold it, thereby allowing tau to be
degraded by other chaperone machinery. Further examinations of the mechanism
behind Aha1 mediated tau reductions are needed.
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This work has demonstrated the relevance of Aha1 knock-down in vivo. Future
studies could use Aha1 specific inhibitors in vivo to further progress this work. Overall,
this study demonstrates that Aha1 inhibition is an important therapeutic target for
treating tauopathies.
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Figure 4.1. Generating shRNA-Aha1 AAV9. (A) N2A cells were transfected with
shRNA-Aha1 plasmids and allowed to express for 48hr before harvesting and samples
were run by Western blot. (B) Quantification of Aha1 protein reduction after treatment
with shRNA. (C) Schematic of viral construct and delivery method.
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Figure 4.2. Viral transduction results in reduced Aha1 levels. (A) Samples of lowspeed spin from each mouse hippocampi were analyzed by Western blot to check Aha1
knock-down. (B) Quantification of Western blot Aha1 levels relative to Actin control
levels (results represent the mean ± SEM; scrambled, n=8; shAha1, n=8; *p < 0.05). (C)
Representative image of Aha1 expression from AAV9-scrambled and AAV9-shAha1
mice. Scale bars represent 300 µm for the whole slice and 100 µm for the inset. (D)
Quantification of the Aha1 positive area in the hippocampal field of view (results
represent the mean ± SEM; scrambled, n=8; shAha1, n=6; *p < 0.05).
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Figure 4.3. Aha1 knock-down decreases Gallyas silver positive tau tangles. (A)
Representative images of brain tissue slices stained with Gallyas silver from AAV9scrambled and AAV9-shAha1 mice. Scale bars represent 300 µm for the whole slice
and 100 µm for the inset (B) Quantification of the Gallyas silver positive area in the
hippocampal field of view (results represent the mean ± SEM; scrambled, n=8; shAha1,
n=6; p=0.05).
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Figure 4.4. Preservation of hippocampal CA1 neurons seen with Aha1 knockdown. (A) Representative images of NeuN stained neurons in the CA1 region of the
hippocampus (black) counter stained with creysl violet (purple) from AAV9-scrambled
and AAV9-shAha1 mice. Scale bars represent 150 µm for the whole slice and 50 µm for
the inset. (B) Quantification of unbiased stereology (results represent the mean ± SEM;
scrambled-WT, n=8; shAha1-WT, n=8; scrambled-rTg4510, n=8; shAha1-rTg4510 n =6;
*p < 0.05).
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Figure 4.5. Aha1 knock-down reduces phosphorylated tau. (A) Representative
images of pS396/404 stained tissue from AAV9-scrambled and AAV9-shAha1 mice.
Scale bars represent 300 µm for the whole slice and 100 µm for the inset. (B)
Quantification of pS396/404 positive area from hippocampal field of view (results
represent the mean ± SEM; scrambled, n=8; shAha1, n=6; **p < 0.01). (C)
Representative images of AT8 stained tissue from AAV9-scrambled and AAV9-shAha1
mice. Scale bars represent 300 µm for the whole slice and 100 µm for the inset. (D)
Quantification of AT8 positive area from hippocampal field of view (results represent the
mean ± SEM; scrambled, n=8; shAha1, n=6; **p < 0.01).
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Figure 4.6. Aha1 knock-down does not lead to altered total tau levels. (A)
Representative images of total human tau stained tissue from AAV9-scrambled and
AAV9-shAha1 mice. Scale bars represent 300 µm for the whole slice and 100 µm for
the inset. (B) Quantification of total human tau positive area from hippocampal field of
view (results represent the mean ± SEM; scrambled, n=8; shAha1, n=6; ns=nonsignificant).
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Figure 4.7. No reductions seen in oligomeric tau from Aha1 knock-down. (A)
Representative images of TOC1 stained tissue from AAV9-scrambled and AAV9shAha1 mice. Scale bars represent 300 µm for the whole slice and 100 µm for the inset.
(B) Quantification of TOC1 positive area from hippocampal field of view (results
represent the mean ± SEM; scrambled, n=8; shAha1, n=6; **p < 0.01). (C) Dot blot of
hippocampal tissue from individual mice probed by T22. Four representative samples
shown for AAV9-scrambled and AAV9-shAha1. (D) Quantification of dot blot (results
represent the mean ± SEM of individual mouse samples; scrambled, n=6; shAha1, n=6;
ns=non-significant).
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Chapter Five:
Final considerations
This study has identified the Hsp90 co-chaperone, Aha1, as an important
regulator of tau pathology. The major findings in this study demonstrate that Aha1, in
complex with Hsp90, enhances tau aggregation, both in vitro and in vivo. Aha1
overexpression in rTg4510 mice leads to cognitive deficits and neuronal loss, whereas
knock-down of Aha1 in the same mouse model leads to reduced pathological tau and
neuronal preservation. We have shown that Aha1 is co-localized with tau tangles in the
brains of human AD patients, providing a clinical link between Aha1 and tau. This study
supports the need to further characterize drugs which target the Hsp90/Aha1 interaction
as a therapeutic option for the treatment of AD and other tauopathies.
The Hsp90 chaperone network is highly involved in tau pathology, especially in
aging and disease. The levels of many Hsp90 chaperone network family members are
altered in aging and AD, suggesting that these changes may be important for agingrelated diseases. Hsp90 has been the main target for modulating tau degradation, but
due to toxicity and bioavailbility of Hsp90 inhibitors there has been no clinical success
with Hsp90 inhibitors. Therefore, it is beneficial to try a different approach using cochaperones, which help with specificity as well as limit the possibility of toxicity. Aha1
appears to be an excellent candidate because inhibitors of Aha1 may have a similar
effect as inhibitors towards Hsp90. Additionally; Aha1/Hsp90 has a much smaller pool of
potential protein interactions, which lessens the chance of toxicities.
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There are some limitations with targeting Aha1 as a disease-modifying treatment
for tauopathies. Currently, while there are small molecule inhibitors of Aha1, none of
them have been tested for their in vivo effectiveness on tau pathology. Additionally,
there is no pharmacokinetic, pharmacodynamics or toxicity data on these inhibitors. So
while the proof-of-concept of Aha1 inhibition is reasonable, further studies into small
molecule Aha1 inhibitors needs to be done. While the mechanism involving Hsp90 and
tau has been well studied, further studies examining the effect of the Hsp90/Aha1
interaction on tau pathology are warranted. It seems counterintuitive that chaperone
proteins would make tau pathology worse; however, that is exactly what several
members of the Hsp90 chaperone network do, including FKBP51, Aha1, and several
others mentioned in Chapter 1. The imbalances seen in the Hsp90 chaperone network
in aging and AD shed some light on the problem, with co-chaperones like FKBP51 and
Aha1 increasing with AD, while others such as CyP40 and PP5 are repressed. It seems
there is a bigger picture between the Hsp90 chaperone network and tau that will need to
be elucidated in order to be able to treat tauopathies.
There is also a potential link between Aha1 and tau through the tyrosine kinase
c-Abl. C-Abl has been shown to modulate tau pathology and according to one study, cAbl phosphorylation of Y223 on Aha1 promotes its interaction with Hsp90. This
suggests that an upregulation of c-Abl could be a possible mechanism behind the
effects of Hsp90/Aha1 on tau pathology. Further studies are needed to fully understand
the link between c-Abl, Aha1 and tau.
In addition to tauopathies, Aha1 has been implicated in other diseases such as
cancer and cystic fibrosis. It would be worthwhile to monitor the progress of Aha1
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therapeutics in these fields as well because advancement in diseases in the periphery
usually occur faster than those of the brain. We could gain useful insights into the
mechanism underlying Aha1 inhibition by studying its application in other diseases.
Overall our findings suggest that the Hsp90/Aha1 complex is integral in
pathological tau accumulation. Using gene silencing of Aha1 we were able to reduce
pathological tau and rescue neuronal loss. This work proves that Aha1 is a worthwhile
target for the treatment of tauopathies and deserves further investigation.
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